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ABSTRACT OF THE DISSERTATION 
Runx1 in Primitive Hematopoiesis and Characterization of Hematopoietic Stem 
Cells in a Mouse Chronic Inflammatory Arthritis Model 
by 
Yunglin David Ma 
Doctor of Philosophy in Biology and Biomedical Sciences 
Program in Developmental Biology 
Washington University in St. Louis, 2009 
Professor Kyunghee Choi, Chairperson 
 
Hematopoietic cells are essential for growth and survival throughout adult life. 
Two different aspects of hematopoiesis are addressed in this dissertation. 
I. The regulation of primitive hematopoiesis by Runx1 and TGFβ signaling. 
Primitive hematopoiesis, occurring exclusively in the yolk sac, is characterized 
by its transient nature. As the primitive hematopoiesis declines in the yolk sac, 
definitive hematopoietic progenitors generated in the yolk sac and/or embryo take 
over in blood cell production. Whether the transition from primitive to definitive 
hematopoietic program reflects a mere shift in hematopoietic sites or whether it is an 
actively regulated process is currently unknown. Runx1 is necessary for the 
establishment of definitive hematopoiesis. Most studies on Runx1 have focused on 
its role in generating hematopoietic stem cells. Intriguingly, Runx1 expression can be 
detected in the yolk sac blood-islands where primitive erythroid (EryP) progenitors 
emerge. The function of Runx1 in primitive hematopoiesis has not been carefully 
investigated. Herein, we determined if Runx1 plays a role in primitive hematopoiesis 
 xii 
by utilizing in vitro embryonic stem (ES) cell differentiation system and by examining 
EryP development in Runx1 mutant mice. We demonstrated that Runx1 deficient 
mice contained a significantly reduced number of EryP progenitors compared to 
controls. Nonetheless, Runx1 deficient mice survived until they required definitive 
hematopoietic cells. We demonstrated that a high level of enforced Runx1 expression in 
the in vitro differentiation model of embryonic stem (ES) cells suppressed EryP 
progenitor generation. We also identified TGFβ1 as a cooperative signal of Runx1 in 
negatively regulating EryP development. Our studies revealed an unexpected role of 
Runx1 in both initiation and termination of primitive hematopoiesis. 
II. The relationship between hematopoietic stem cells and bone marrow 
microenvironment. 
There is an intricate relationship between hematopoiesis and bone homeostasis 
in normal physiological states during adulthood. By utilizing mice undergoing chronic 
inflammatory arthritis, we investigated the relationship between hematopoiesis and 
bone homeostasis in pathological conditions. We demonstrated that mice with 
chronic inflammatory arthritis are osteoporotic due to a severe defect in osteoblast 
function. Despite the defective osteoblast function, the hematopoietic stem cells from 
these mice exhibited normal properties in HSC frequency, cell cycling and long-term 
repopulating ability. Therefore, the bone forming capacity of osteoblasts is 
disassociated from their ability to maintain HSCs in a chronic inflammatory condition. 
These observations suggest other cell types, such as endothelial cells in the bone 
marrow, might serve as HSC niches under pathological conditions. 
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Chapter 1 
Runx1 in Primitive Hematopoiesis 
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Chapter 1.1 
Introduction 
 
 3 
Hematopoietic Development during Mouse Embryogenesis 
The production of blood cells takes place in several distinct anatomical sites 
during mouse embryogenesis. The first blood cells to appear, known as primitive 
erythrocytes, are initially detectable in the extraembryonic yolk sac blood islands 
at embryonic day E7.5 of gestation and become extinct by E9.0. (Ferkowicz and 
Yoder, 2005). Meanwhile, the liver rudiment is colonized by hematopoietic stem 
cells by E10.5 and becomes the principal hematopoietic organ during fetal 
development (Houssaint, 1981). Beginning at birth, bone marrow (BM) is 
colonized by hematopoietic stem cells (HSCs) originating from the fetal liver. 
Thereafter, and continuing throughout adult life, all mature blood cells are 
produced in the bone marrow. The term primitive hematopoiesis is applied to the 
development of the initial yolk sac-derived erythroid cells, while definitive 
hematopoiesis refers to all blood cell lineages other than the primitive erythroid 
cells (Keller et al., 1999). 
The blood islands are composed of both primitive erythroid cells (EryP) and 
endothelial cells, which constitute a small fraction of the whole yolk sac vascular 
system. The close developmental association of the hematopoietic and 
endothelial cell lineages within the yolk sac blood islands of the developing 
embryo has led to the hypothesis that they arise from a common precursor, 
termed the hemangioblast (Park et al., 2005; Sabin, 1920). Cell tracking studies 
indicate that hemangioblast development begins in the primitive streak, after 
which they migrate into the yolk sac blood islands (Huber et al., 2004). EryP cells 
are generated from a transient wave of progenitors, termed primitive erythroid 
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colony-forming cells (EryP-CFC), found exclusively in the yolk sac between E7.25 
and E9.0 (Palis et al., 1999). Primitive erythrocytes (EryP) are larger than 
definitive erythrocytes (EryD). They are initially circulating as nucleated cells, and 
mainly express two embryonic forms of β-globin proteins (εy and βH1), as well as 
both embryonic and adult forms of α-globin proteins (ζ and α, respectively) 
(Kingsley et al., 2006). However, recent studies demonstrate that primitive 
erythrocytes undergo enucleation between E12.5 and 16.5, producing mature 
primitive erythrocytes that are comparable in size to definitive erythrocytes 
(Kingsley et al., 2004). In the fetal liver, hematopoietic progenitors generate 
definitive erythrocytes, as well as myeloid and lymphoid cells. Definitive erythroid 
cells are smaller than EryP, enucleated, and express a range of adult globin 
isoforms, namely α1, α2, β1 and β2 (Lensch and Daley, 2004; Palis et al., 1999). 
 Genetic knock-out mice have provided insight into the functions of various 
genes in the generation and maintenance of primitive erythroid cells. Deficiencies 
of Scl, Lmo2, or Gata2 in mouse embryos result in mid-gestational embryonic 
lethality due to failure of or defective emergence of primitive hematopoiesis 
(Porcher et al., 1996; Robb et al., 1995; Shivdasani et al., 1995; Tsai et al., 1994; 
Warren et al., 1994; Yamada et al., 1998). The Gata1 transcription factor has an 
essential role in the regulation of erythroid-specific genes in both primitive and 
definitive erythroid cells. Gata1-deficient mice and differentiated embryonic stem 
(ES) cells derived from Gata1-deficient mice cannot generate mature erythroid 
cells due to developmental arrest and cell death at the proerythroblast stage 
(Fujiwara et al., 1996; Pevny et al., 1991). Mice deficient in erythroid Krupple-like 
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factor (Eklf) have severe defects in definitive hematopoiesis, and recent studies 
show that Eklf is also involved in primitive hematopoiesis (Basu et al., 2007; 
Hodge et al., 2006; Nuez et al., 1995; Perkins et al., 1995). However, some 
transcription factors have been shown to affect only definitive hematopoiesis 
without impacting primitive hematopoiesis. For example, mice lacking c-myb have 
normal primitive erythroid cells but die around day E15.0 with a severely anemic 
phenotype, due to a failure to generate definitive erythrocytes (Mucenski et al., 
1991). Mice deficient in PU.1 also show normal primitive hematopoiesis, but they 
display multiple defects in the development of lymphoid and myeloid cells, dying 
by day E18.5 (Scott et al., 1997). These results suggest that the molecular 
mechanisms governing primitive and definitive hematopoiesis might be differently 
regulated. 
 Generation of hematopoietic stem cells (HSCs) with the ability to produce all 
types of adult blood cells is the key feature of definitive hematopoiesis. The 
origins of the HSCs that initially colonize the fetal liver remain controversial. There 
are currently two major models concerning the source of HSCs. The first model is 
that the HSCs emerge from within the yolk sac and then migrate to the fetal liver, 
subsequently populating the bone marrow. The second model is that the HSCs 
that enable fetal liver hematopoiesis emerge from within the intraembryoic 
para-aortic-splanchnopleure (PAS)/aorta-gonad-mesonephros (AGM) region. 
 Support for the first model comes from studies showing that the yolk sac 
contains multiple definitive hematopoietic progenitors, including T cells, B cells, 
and myeloid cells, even before the embryonic circulation starts (Cumano et al., 
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1993; Huang and Auerbach, 1993; Liu and Auerbach, 1991; Wong et al., 1986). 
Moreover, Lux et al. used Ncx1-null embryos, which lack a heartbeat and, thus, 
have no functional circulation, to demonstrate that Ncx1-/- yolk sacs contain 
normal numbers of both primitive and definitive erythroid progenitors (Lux et al., 
2008). There were few definitive erythroid progenitors found within the embryo 
proper of the Ncx1-/- mice, supporting the hypothesis that all definitive 
hematopoietic progenitors are initially generated in the yolk sac and migrate out 
into other areas of the embryo with the onset of embryonic circulation. However, 
these studies did not demonstrate that cells arising from the yolk sac during early 
development have long-term repopulating ability, which is the key feature of HSCs. 
Interestingly, when Yoder et al. transplanted E9.0 or E10.0 yolk sac cells into 
neonatal mice to show that yolk sac cells contain long-term repopulating 
hematopoietic stem cells (Yoder and Hiatt, 1997; Yoder et al., 1997a; Yoder et al., 
1997b). In contrast, transplantation of E10.0 yolk sac cells into adult recipients did 
not result in engraftment (Yoder and Hiatt, 1997). These observations suggest 
that hematopoietic stem cells do emerge from the yolk sac, they require an 
embryonic environment to develop and that the adult microenvironment may not 
support the differentiation of the HSCs generated from the yolk sac. Consistent 
with this interpretation, yolk sac-derived cells can reconstitute the adult 
hematopoietic system when precultured on AGM-derived stromal cells (Matsuoka 
et al., 2001). Recently, using a non-invasive, pulse-labeling technique, 
Samokhvalov et al. were able to demonstrate that yolk sac cells, marked during 
early embryogenesis, can contribute to adult HSC populations that persist for at 
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least 15 months after birth (Samokhvalov et al., 2007). These studies support the 
contention that HSCs arise from within the yolk sac. 
There are also studies which support the model that HSCs that colonize the 
fetal liver originate from in the PAS/AGM region of the embryo (reviewed in 
Cumano and Godin, 2007). Godin et al. surgically removed the PAS/AGM regions 
from E8.5-E9.0 embryos and embedded them under the kidney capsules of SCID 
mice (Godin et al., 1993). Afterwards, they could detect serum immunoglobulin M 
(IgM), IgM-secreting plasma cells, and B cells of the B1a phenotype of donor 
origin 3-6 months after the engraftment. Furthermore, when culturing cells from 
the PAS/AGM region and from yolk sac isolated prior to the establishment of 
circulation, the PAS/AGM cells give rise to much higher numbers of myeloid and 
lymphoid cells than do the yolk sac cells (Cumano et al., 1996; Godin et al., 1995). 
More importantly, the AGM region contains spleen colony-forming cell (CFU-S) 
activity, which measures numbers of definitive hematopoietic progenitors, at a 
higher level than that what is seen in the extraembryonic yolk sac (Medvinsky et 
al., 1993). Importantly, the PAS region from precirculation stage or the AGM 
region from E10.0 embryos contain long-term repopulating HSCs but the yolk 
sacs do not (Cumano et al., 2001; Medvinsky and Dzierzak, 1996). It has been 
shown that HSCs emerge first from the dorsal aorta of the AGM region (E10.5), 
followed by emergence in the vitelline and umbilical arteries (de Bruijn et al., 
2000). These studies demonstrated that HSCs emerge within the embryo proper, 
not from the yolk sac, to establish definitive hematopoiesis. In addition, several 
studies have suggested that HSCs may also emerge from the placenta 
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(Alvarez-Silva et al., 2003; Rhodes et al., 2008; Zeigler et al., 2006). Moreover, 
endothelial cells from all three tissues, AGM, yolk sac and placenta, have recently 
been proposed to be responsible for the generation of hematopoietic stem cells 
(Chen et al., 2009; Eilken et al., 2009; Lancrin et al., 2009; Zovein et al., 2008). 
Intriguingly, when HSCs emerge and definitive hematopoiesis begins, 
primitive erythroid progenitors become extinct in aging yolk sac (Palis et al., 1999). 
This raises an interesting question as to what mechanism regulates the transition 
from primitive to definitive hematopoiesis. Whether the transition from the 
primitive to the definitive hematopoiesis reflects a mere shift in hematopoietic 
sites or whether it is an actively regulated process is currently unknown. 
 
In vitro Embryonic Stem Cell Differentiation Systems 
To understand the molecular mechanisms regulating early events in the 
developing embryo has been of great interest to investigators. Due to the nature 
of the rapid developmental sequence during embryogenesis, the difficulties of 
accessing embryonic tissues and to the limited availability of cells from early 
embryos, the usage of embryonic tissues and cells to study the molecular 
regulation of hematopoiesis in developing embryos has proven quite challenging. 
Moreover, genetic knock-outs of hematopoiesis-related genes result in embryonic 
lethality, precluding further analyses of tissues from knockout animals (Okuda et 
al., 1996; Pevny et al., 1991; Shivdasani et al., 1995; Tsai et al., 1994; Wang et al., 
1996a). Therefore, in vitro studies of embryonic stem (ES) cell differentiation have 
been utilized as an alternative method to study early events of embryonic 
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hematopoietic development. 
ES cells can divide and differentiate in liquid differentiating media readily to 
generate sphere-like, differentiated cells masses call embryoid bodies (EBs, 
Figure 1.1-1, reviewed in Choi, 2002; Keller et al., 1999). ES cells can also be 
differentiated on layers of stromal cells or in dishes coated with type IV collagen 
without forming the EB structure (Nishikawa et al., 1998). EBs contain cells of all 
three germ layers (mesoderm, endoderm, and ectoderm) and can be further 
differentiated into many different lineages including cardiac, smooth and skeletal 
muscle; neuronal; endothelial; and hematopoietic lineages (Choi, 2002; Keller et 
al., 1993; Vittet et al., 1996). Among these lineages, the hematopoietic cells have 
been the most extensively characterized. 
Many molecular and cellular studies have revealed that the sequential 
development of early hematopoietic events in differentiated ES cells is similar to 
that found in the normal developing embryo (Faloon et al., 2000; Keller et al., 
1993; Palis et al., 1999). For example, as in the developing embryo, the primitive 
erythroid progenitors emerge prior to definitive hematopoietic progenitors (Keller 
et al., 1993; Palis et al., 1999). Additionally, testing the effects of specific soluble 
factors or inhibitors in the ES-EB system enables investigators to develop further 
understanding about the roles of different signaling pathways in the development 
of various cell types of interest (Lee et al., 2008; Lengerke et al., 2008; Nostro et 
al., 2008). For these reasons, among others, the in vitro differentiation model of 
ES cells is a powerful system for studying early embryonic development. 
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Transforming Growth Factor beta (TGFβ) Signaling in Embryonic 
Hematopoiesis 
 Numerous studies demonstrate that the transforming growth factor-β (TGFβ) 
superfamily, including TGFβ, bone morphogenetic protein (BMP), and activin, is 
critical for hematopoietic and vascular development (Larsson and Karlsson, 2005; 
Shi and Massague, 2003). Members of the TGFβ superfamily bind to the 
transmembrane heterodimeric complexes of Type I and Type II serine/threonine 
kinase receptors to transduce their signals (Figure 1.1-2, Shi and Massague, 
2003). Type II receptor kinases are constitutively active, while Type I receptors, 
also known as activin receptor-like kinases (ALKs), contain an inactive kinase 
domain (Shi and Massague, 2003). When the ligands bind to their cognate 
receptors as dimers, the constitutively active Type II receptor transphosphorylates 
and activates the kinase domain of type I receptors (Wrana et al., 1994). The 
phosphorylated type I receptor will then phosphorylate either 
SMAD1/SMAD5/SMAD8 or SMAD2/SMAD3, the receptor-specific SMADs 
(R-SMADs, Heldin et al., 1997). The phosphorylated R-SMADs will then partner 
with SMAD4, the common SMAD (Co-SMAD), and translocate into the nucleus 
where the SMAD complex interact with specific transcription factors to regulate 
the transcription of their target genes (Heldin et al., 1997). SMAD6 and SMAD7 
are inhibitory SMADs (I-SMADs) and can inhibit the activated R-SMADs. SMAD6 
preferentially inhibits the BMP SMADs (SMAD1/5/8) while SMAD7 blocks the 
activity of all R-SMADs (Hata et al., 1998; Hayashi et al., 1997; Ishisaki et al., 
1999; Nakao et al., 1997).  
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There are three mammalian isoforms of TGFβs: TGFβ1, TGFβ2,and 
TGFβ3, of which TGFβ1 is the most abundant. During embryogenesis, as early as 
E7.5, TGFβ1 can be detected in blood islands in the yolk sac, in mesodermal cells 
of the allantois, and in the pro-angioblast progenitors within the cardiogenic 
mesoderm of the embryo (Akhurst et al., 1990). At later stages of the developing 
embryo, TGFβ1 expression is detectable in fetal liver, endothelial, epithelial, and 
osteogenic tissues (Akhurst et al., 1990; Lehnert and Akhurst, 1988). 
TGFβ1-deficient mice display severe defects in their yolk sacs, including 
abnormal vascular structures and in significantly reduced numbers of erythroid 
cells, leading to embryonic lethality in the period between E9.5-E11.5 (Dickson et 
al., 1995). Intriguingly, Tgfβ receptor II (TgfrII) expression largely correlates with 
the expression patterns of Tgfβ1 (Lawler et al., 1994), and a homozygous 
deficiency of TgfβrII results in embryonic lethality with defects in yolk sac 
hematopoiesis and vasculogenesis, which are similar to the defects seen in 
homozygous Tgfβ1 deficient mice (Oshima et al., 1996). Whether the primary 
cause of death of Tgfβ1-/- or TgfrII-/- mice is due to defects in vasculogenesis or in 
hematopoiesis is not clear. 
Studies have shown that TGFβ1 can bind to its cognate receptors TGFβrI 
(ALK5) and TGFβrII to form a complexes that activate the SMAD2/SMAD3 
pathway (Heldin et al., 1997). In addition to signaling through ALK5, TGFβ1 can 
also bind to ALK1 and TGFβrII to form a complex which activates the SMAD1/5/8 
pathway (Lux et al., 1999; Oh et al., 2000). Recent studies demonstrated that the 
expression patterns of ALK1 and ALK5 are mutually exclusive in blood vessels 
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(Seki et al., 2006). Specifically, ALK1 expression was detected in arterial 
endothelium, whereas ALK5 expression was detected in mesenchymal tissue and 
smooth muscle cells surrounding the aorta, but was undetectable in the 
endothelial cells (Seki et al., 2006). These findings suggest that ALK1 and ALK5 
might possess distinct biological roles in the developing embryo. Both Alk1 and 
Alk5 knock-out mice die at similar mid-gestation stages, the period E9.5-E10.5, 
with severe defects in vascular development of the yolk sac and an absence of 
circulating red blood cells (Larsson et al., 2001; Oh et al., 2000; Seki et al., 2006). 
Intriguingly, in contrast to the severe anemia seen in the yolk sac and in the 
embryo proper of these mice, when Alk5-/- yolk sac cells were assayed in vitro, a 
significant increase, relative to numbers in wild-type mice, of erythroid 
colony-forming cells was detected (CFU-Ery), whereas numbers of 
granulocyte-macrophage colony-forming cells (CFU-GM) and mixed 
colony-forming cells (CFU-Mix) appeared to be normal (Larsson et al., 2001). 
These studies suggest that TGFβ signaling could have an inhibitory effect on the 
formation and/or proliferation of erythroid progenitors. Consistent with this 
observation, Park et al. showed that TGFβ1 inhibits BMP4 and VEGF-mediated 
hematopoietic induction in the ES-EB system (Park et al., 2004). 
Moreover, inactivation of Smad4 within Flk1-expressing cells, which can 
generate both primitive and definitive blood cells, results in a 50% reduction of 
various hematopoietic progenitors in the yolk sac (Park et al., 2006). Smad2 
knock-out embryos die during early embryonic development due to defective 
mesoderm formation, from which the hematopoietic lineages normally arise 
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(Nomura and Li, 1998; Waldrip et al., 1998; Weinstein et al., 1998). Inhibition of 
Smad5 can neutralize the suppressive effects of TGFβ on adult hematopoietic 
progenitors, so the data suggest that, apart from Smad2 and Smad3, Smad5 
could also be a mediator of TGFβ signaling in hematopoietic cells (Bruno et al., 
1998). Deletion of Smad5 in mice results in embryonic lethality around 
mid-gestation with reduced numbers of blood cells and defective vascular 
structure in the yolk sac, which is similar to what is observed in knock-out animals 
for the TGFβ receptors (Chang et al., 1999; Yang et al., 1999). However, in vitro 
replating assays showed that yolk sacs from Smad5-/- embryos had increased 
numbers of high-proliferative-potential colony-forming cells (HPP-CFCs) with 
enhanced replating potential, and also contained augmented hematopoietic 
progenitors (Liu et al., 2003). Intriguingly, differentiated ES cells derived from 
Smad5-/- mice contained an elevated number of blast colony-forming cells 
(BL-CFCs), the in vitro equivalents of hemangioblasts, in contrast to reduced 
numbers of EryP progenitors (Liu et al., 2003). Collectively, these studies suggest 
that TGFβ signaling has a regulatory role in hematopoietic development during 
embryogenesis, but the detailed mechanism of this regulation is not clear at this 
time. 
 
Runx1 in Hematopoietic Development 
Runx1, also known as Aml1, belongs to the core binding factor (CBF) 
transcription factor family, which consists of three DNA-binding CBFα subunits 
(Runx1, Runx2, and Runx3) and a common, non-DNA binding subunit, CBFβ 
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(Speck and Gilliland, 2002). Runx1 contains a highly conserved domain with 
homology to Runt, the Drosophila paired-rule gene and it binds to the TGT/CGGT 
DNA sequence (Daga et al., 1992; Meyers et al., 1993). RUNX1 heterodimerizes 
with its molecular partner, CBFβ, through the Runt homology domain (RHD) to 
carry out its transcriptional activity (Meyers et al., 1993; Ogawa et al., 1993; Wang 
et al., 1993). 
Runx1 and its partner, CBFβ, are the most frequent targets of chromosome 
translocations in human acute myeloid leukemia (AML)(Liu et al., 1993; Miyoshi et 
al., 1991). The importance of Runx1 in hematopoietic development was revealed 
from mouse knock-out studies. Runx1-null animals die between E12.5 and E13.5 
due to lack of definitive hematopoiesis and hemorrhaging in the central nervous 
system (Okada et al., 1998; Okuda et al., 1996; Wang et al., 1996a). Definitive 
hematopoietic colonies cannot not be identified in E10.5 or E11.5 Runx1-/- yolk 
sacs, fetal liver, or Runx1-/- EB cells (Wang et al., 1996a). Generation of chimeric 
animals by injecting Runx1-/- ES cells into wild-type blastocysts demonstrated that 
Runx1-/- ES cells were unable to produce any hematopoietic tissues while these 
cells can contribute to other non-hematopoietic organs (Okuda et al., 1996). 
These studies indicate that the defects of the Runx1 knock-out cells are specific to 
failures in the hematopoietic lineages, and not to defects in the fetal liver 
microenvironment. In addition, knock-out studies of CBFβ show a parallel 
phenotype to Runx1-deficient mice, suggesting that CBFβ is essential for RUNX1 
function during early embryogenesis (Sasaki et al., 1996; Wang et al., 1996b). 
To further understand the role of Runx1 during early embryogenesis, 
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Runx1lacZ/+ mice and in situ hybridization were used. The expression of Runx1 is 
first detectable in extraembryonic mesodermal cells at E7.25 and then in both 
primitive erythrocytes and endothelial cells of the yolk sac blood islands at 
E8.0-E8.5 (Lacaud et al., 2002; North et al., 1999). Between E8.5-E11.5, Runx1 
can be detected in endothelial cells and mesenchymal cells in the yolk sac, in the 
vitelline and umbilical arteries, and in the ventral aspect of the dorsal aorta in the 
AGM region where hematopoietic stem cells (HSCs) were first identified (North et 
al., 1999). Subsequent studies confirmed that Runx1 is required for the 
emergence of HSCs during embryonic development (North et al., 1999; North et 
al., 2002; Yokomizo et al., 2001). Interestingly, E9.5-E11.5 Runx1+/- embryos 
show significantly reduced numbers of definitive hematopoietic progenitors in their 
livers and yolk sacs, compared to wild-type controls (Cai et al., 2000; Mukouyama 
et al., 2000). Additionally, HSCs emerge prematurely in the E10.0 Runx1+/− yolk 
sacs, and there was a premature termination of HSC activity in the Runx1+/− AGM 
explants (Cai et al., 2000; North et al., 2002). These observations indicate that the 
degree of RUNX1 activity is critical for temporal and spatial regulation of the 
generation of HSCs during hematopoietic development. Although Runx1 starts 
being expressed during the period when EryP progenitors are forming, what role 
Runx1 plays in murine primitive hematopoiesis is currently unclear. 
However, studies of Runx1 in Xenopus and zebrafish indicate important roles 
of Runx1 in primitive hematopoiesis in those animals. Runx1 expression is among 
the earliest molecular markers for blood in Xenopus, and the introduction of the 
Runt domain from the Xenopus Runx1 homologue, Xaml, into Xenopus embryos 
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results in the disruption of normal primitive hematopoiesis (Tracey et al., 1998). 
Studies in zebrafish also demonstrate that Runx1 is involved in both primitive and 
definitive hematopoiesis (Kalev-Zylinska et al., 2002). These findings suggest that 
Runx1 may also function in mouse primitive hematopoietic development. 
Previous studies have also demonstrated that RUNX proteins, including 
RUNX1, RUNX2 and RUNX3, have cooperative interactions with TGFβ 
superfamily signaling in several biological systems (Ito and Miyazono, 2003). 
Specifically, both Runx1 and Runx3 expression can be induced by TGFβ1, and 
they interact with FOXO3 to induce Bim expression to mediate apoptosis in 
hepatic (Wildey and Howe, 2009) and gastric epithelial cells (Yano et al., 2006). 
Moreover, Runx2 can physically interact with BMPs-specific SMADs, including 
SMAD1 and SMAD5, to cooperatively induce osteoblast differentiation of 
mesenchymal progenitor cells (Lee et al., 2002; Lee et al., 2000; Zhang et al., 
2000). Taken together, these studies suggest that there is, at the very least, 
possible crosstalk between Runx1 and TGFβ signaling. 
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Overall Goals of Chapter One 
  Hematopoietic development is composed of two waves of hematopoiesis: 
primitive and definitive. Primitive hematopoietic progenitors emerge exclusively 
and transiently in the yolk sac during embryogenesis. While primitive 
hematopoietic progenitors become distinct in aging yolk sac, definitive 
hematopoietic progenitors generated in the yolk sac and/or embryo take over 
blood cell production in later embryonic development and throughout adult life. 
Runx1 is essential for the establishment of definitive hematopoiesis, but its 
expression is also detectable in the yolk sac blood islands, where primitive 
hematopoiesis occurs. Little is known about the role of Runx1 in primitive 
hematopoiesis. Thus, the objective of this chapter was to elucidate the role of 
Runx1 in primitive hematopoiesis, using in vitro ES cell differentiation systems 
and Runx1 mutant mice. In addition, TGFβ1 has been suggested as a regulator of 
primitive hematopoiesis. TGFβ signaling has been show to function cooperatively 
with Runx family in other biological systems. Therefore, the question was 
explored of whether TGFβ1 and Runx1 have a cooperative relationship in the 
regulation of primitive hematopoiesis. 
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Figure 1.1-1. 
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Figure 1.1-1. In vitro embryonic stem cell differentiation systems. 
Schematic diagram of in vitro ES cell differentiation systems. ES cells can be 
differentiated in vitro and give rise to differentiated cell masses called embryoid 
bodies (EBs). EBs are composed of multiple cell types, as indicated by different 
colors. Many cellular and molecular analyses can be performed on EBs such as 
hematopoietic colony assay, biochemical analysis, quantitative reverse 
transcription polymerase chain reaction (qRT-PCR), or flow cytometry (FACS 
analysis). 
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Figure 1.1-2. 
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Figure 1.1-2. A schematic diagram of TGFβ superfamily ligands, their type I 
and type II receptors, and downstream SMAD molecules (modified from Shi 
and Massague, 2003). 
Members of the TGFβ superfamily bind to the transmembrane heterodimeric 
complexes of Type I and Type II serine/threonine kinase receptors to transduce 
their signals. Type II receptor kinases are constitutively active, while Type I 
receptors, also known as activin receptor-like kinases (ALKs), contain an inactive 
kinase domain. When the ligands bind to their cognate receptors as dimers, the 
constitutively active Type II receptor transphosphorylates and activates the kinase 
domain of type I receptors. The phosphorylated type I receptor will then 
phosphorylate either SMAD1/SMAD5/SMAD8 or SMAD2/SMAD3, the 
receptor-specific SMADs (R-SMADs). The phosphorylated R-SMADs will then 
partner with SMAD4, the common SMAD (Co-SMAD), and translocate into the 
nucleus where the SMAD complex interact with specific transcription factors to 
regulate the transcription of their target genes. SMAD6 and SMAD7 are inhibitory 
(I-SMADs) and can inhibit the activated R-SMADs. 
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Abstract 
Primitive hematopoiesis, also known as primitive erythropoiesis, occurs 
exclusively in the yolk sac and is characterized by its transient nature. Primitive 
erythroid (EryP) progenitors emerge from the yolk sac by the end of gastrulation, 
undergo extensive proliferation and differentiation and become extinct by 
embryonic day 9. By this time, definitive hematopoietic progenitors generated in 
the yolk sac and/or embryo produce blood cells that represent definitive 
hematopoiesis. Runx1 is critical for the emergence of definitive hematopoiesis. 
Herein, we determined the role of Runx1 in primitive hematopoiesis. We 
demonstrate that a high level of enforced Runx1 expression in the in vitro 
differentiation model of embryonic stem (ES) cells suppressed EryP progenitor 
generation. Unexpectedly, both Runx1 null ES and yolk sacs produced a greatly 
reduced number of EryP progenitors. Furthermore, Runx1 DNA and CBFβ 
binding were required for optimal EryP generation from the yolk sac. In both 
Runx1 null and overexpression ES systems, the reduction in EryP progenitor 
formation coincided with down regulation of Gata1 and Eklf. Introduction of Gata1 
or Eklf partially rescued EryP defects seen in Runx1 null or overexpression 
system. TGFβ1 treatment led to Runx1 upregulation and suppression of EryP 
formation. Alk5, a type-I TGFβ1 receptor, was highly expressed in EryP cells and 
Alk5 deficient ES cells generated a higher EryP progenitor number. Collectively, 
we demonstrate that optimal EryP production is sensitive to Runx1 expression 
level. 
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Introduction 
During mouse development, hematopoietic cells are generated from several 
distinct anatomic sites: yolk sac, embryonic blood vessels including the aorta-
gonad-mesonephros region, fetal liver and bone marrow. The first emerging 
mature hematopoietic cells, designated as primitive erythrocytes (EryP), are 
exclusively produced in the yolk sac. The primitive erythropoiesis is quickly 
replaced by adult type hematopoiesis, termed “definitive”. While EryP is believed 
to develop from mesodermal progenitors, definitive hematopoiesis is established 
by hematopoietic stem cells (HSCs). Whether HSCs originate from the yolk sac, 
aorta/genital ridge/mesonephros (AGM) or placenta is an actively investigated 
area (Cumano et al., 2001; de Bruijn et al., 2000; Lux et al., 2008; Rhodes et al., 
2008; Samokhvalov et al., 2007). 
 
EryP cells are characterized by the expression of embryonic globin genes. EryP 
progenitors in the yolk sac can be detected as early as embryonic day (E) 7.5, 
undergo extensive proliferation and differentiation in a synchronous manner and 
become extinct by E9.0 (Palis et al., 1999). Recent studies have established that 
EryP cells also enucleate, similar to adult globin expressing definitive erythroid 
(EryD) cells, during maturation in circulation (Fraser et al., 2007; Kingsley et al., 
2004). It is possible that EryP extinction merely reflects the hematopoietic site 
shift from the yolk sac to other organs, such that EryP progenitors are no longer 
produced from aging yolk sacs. However, as definitive hematopoiesis ensues 
concomitant to the cessation of primitive hematopoiesis in the yolk sac (Kingsley 
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et al., 2006; Palis et al., 1999), it is possible that transition from primitive to 
definitive hematopoiesis could be an active process, which is molecularly 
regulated.  
 
Runx1, also known as AML1, is the most frequent target of chromosome 
translocations in human acute myeloid leukemia (AML)(Miyoshi et al., 1991). 
Runx1 belongs to the core binding factor (CBF) transcription factor family. This 
family contains a common non-DNA binding CBFβ subunit and three CBFα 
members, Runx1, 2 and 3 (Speck and Gilliland, 2002). The mammalian RUNX 
proteins contain a highly conserved Runt domain, which functions in DNA binding, 
CBFβ subunit interactions, and ATP binding (Crute et al., 1996). By applying site-
directed mutagenesis, Nagata and Werner have identified specific amino acids 
for the DNA-binding and heterodimerization of the Runt domain of RUNX1 
(Nagata and Werner, 2001). Previous studies have demonstrated that Runx1-/- 
animals die between E11.5 and E13.5 and display lack of definitive 
hematopoiesis and hemorrhage in the central nervous system (Okuda et al., 
1996; Wang et al., 1996). The chimeric animals generated between Runx1-/- ES 
cells and wild-type blastocysts showed no contribution of Runx1-/- ES cells to any 
hematopoietic tissues despite their contributions to other tissues (Okuda et al., 
1996). Importantly, Runx1 deficient embryos failed to generate hematopoietic 
clusters, which arise from the ventral side of the dorsal aorta in the AGM region 
(North et al., 1999). Collectively, these studies have demonstrated that Runx1 is 
essential for the emergence of definitive hematopoiesis.  
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 Accumulating studies indicate that the TGFβ superfamily of growth factors is 
critical for hematopoietic and vascular development (Larsson and Karlsson, 
2005). During early embryonic development, TGFβ1 expression can be detected 
in the yolk sac blood islands, the mesodermal cells of the allantois, and the 
cardiac mesoderm of the embryo (Akhurst et al., 1990). Upon binding type II 
receptor, TGFβ induces heteromeric receptor complex formation with type I 
transmembrane serine-threonine kinases. Activated type I receptors, Alk1 and 
Alk5, phosphorylate cytoplasmic receptor-associated SMAD proteins (R-SMADs), 
SMAD1/5/8 and SMAD2/3, respectively (Shi and Massague, 2003). Both Tgfβ1 
and TgfβrII deficient mice, which die around E10.5, display anemia with severe 
reductions of mature erythrocytes and defective angiogenesis in the yolk sac 
(Dickson et al., 1995; Oshima et al., 1996). While Alk5-/- mice are also anemic, 
they have an increased number of presumably definitive erythroid progenitors, 
indicating that hematopoietic deficiency seen in these mice are indirect due to 
vascular defects (Larsson et al., 2001). We previously reported that TGFβ1 could 
inhibit BMP4 and VEGF mediated hematopoietic induction from in vitro 
differentiating ES cells (Park et al., 2004). These studies suggest that TGFβ1 
signaling is involved in hematopoietic and vascular development and implies that 
TGFβ1 through ALK5 could inhibit the growth and differentiation of erythroid 
progenitors.  
 
By utilizing various Runx1 mutant mice as well as an in vitro differentiation model 
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of ES cells, we investigated whether Runx1, an essential gene for the generation 
of definitive hematopoiesis, could modulate primitive hematopoiesis. Our studies 
demonstrate that Runx1 plays a critical role in EryP development. First, Runx1 
deficient animals generated greatly reduced number of EryP progenitors. Both 
DNA binding and CBFβ interaction of RUNX1 were required for EryP progenitor 
development. Second, a high dosage of RUNX1 during EB differentiation could 
suppress EryP progenitor formation. We also show that TGFβ1 could upregulate 
Runx1 expression and suppressed EryP progenitor formation. Alk5, a type-I 
TGFβ1 receptor, was highly expressed in EryP cells and Alk5 deficient ES cells 
generated a higher EryP progenitor number. Collectively, Runx1 level could be 
important for optimal primitive erythropoiesis. 
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Materials and Methods 
Cell culture and hematopoietic progenitor assays 
We received the Runx1 cDNA (full length mouse Runx1b encoding amino acid 
residues 1-451), J1, Runx1+/-, and Runx1-/- ES cells from Dr. Nancy Speck, the 
Alk1+/- and Alk1-/- ES cells from Dr. Paul Oh, the Alk5+/+ and Alk5-/- ES cells from 
Dr. Stefan Carlson, and the Tgfβ1+/- and Tgfβ1-/- ES cells from Dr. Ashok Kulkarni. 
The inducible RUNX1 ES (iRUNX1) cell was generated as described previously 
(Kyba et al., 2002; Lugus et al., 2007). 
 
Embryonic stem cell culture and in vitro ES differentiation were performed as 
described previously (Ma et al., 2008; Park et al., 2004; Zhang et al., 2005). 
Exogenous RUNX1 was induced in iRUNX1 EB cells with 1.0 μg/ml or indicated 
concentration of doxycycline (Dox; Sigma). The following factors were used in 
differentiation: BMP4 (5 ng/ml; R&D Systems), VEGF165 (10 ng/ml; R&D 
Systems), TGFβ1 (10 ng/ml; R&D Systems), SB431542 (2 μM; TOCRIS 
bioscience), Noggin (50 ng/ml; R&D Systems), DAPT (2 μM added 2 times/day; 
R&D Systems), and Cyclopamine (3 μM; TRC-Canada). 
 
EryP colonies were generated by harvesting EB cells on the indicated day of 
differentiation, dissociating them in trypsin, passaging them through a 20G 
needle 5-7 times, and plating them in methylcellulose containing 10% plasma-
derived serum (PDS, Animal Technologies, Inc. Texas), 12.5 μg/ml ascorbic acid, 
5% protein-free hybridoma medium (PFHM-II; Gibco), L-glutamine (2 mM), 
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transferrin (300 μg/ml; Boehringer Mannheim), MTG (4.5x10-4M), and Epo (2 
units/ml; Amgen). EryP colonies were counted 4-5 days after replating. 
 
Definitive erythroid and myeloid colony assays, day 6 EB cells were replated in 
methylcellulose containing 10% plasma-derived serum (PDS, Animal 
Technologies, Inc. Texas), 12.5 μg/ml ascorbic acid, 5% protein-free hybridoma 
medium (PFHM-II; Gibco), L-glutamine (2 mM), transferrin (200 μg/ml; 
Boehringer Mannheim), MTG (4.5x10-4M), and Epo (2 units/ml; Amgen), together 
with the following cytokines: kit ligand (KL 1% conditioned media), IL-3 (1% 
conditioned media), IL-1 (5 ng/ml), IL-6 (5 ng/ml), IL-11 (5 ng/ml), G-SCF (2 
ng/ml), M-CSF (5 ng/ml) and GM-CSF (3 ng/ml). Blast colonies were generated 
by replating day 2.75 EB cells in the presence of VEGF (5 ng/ml), kit ligand (1% 
conditioned media), and D4T endothelial cell conditioned media (25%). Blast 
colonies and hematopoietic colonies were counted 5-8 days after replating. 
 
Biochemical analysis of iRUNX1 cells 
To determine the induction of RUNX1 protein in iRUNX1 cells, ES cells were 
differentiated in serum with the indicated amount of Dox added on day 3 and 
harvested on day 4. Subsequent steps to detect the inducible RUNX1 were 
performed as previously described (Park et al., 2004). For generation of the 
iRUNX1 ES cells, FLAG tag was added to the N-terminus of RUNX1. The FLAG 
tag antibody (Sigma) was used to detect the induction of exogenous RUNX1. 
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Generation of Runx1 mutant knock-in mice 
Mouse Runx1 cDNA was digested with SacII and ClaI to obtain a 1.2-kb 
fragment of partial coding sequence containing 62bp of exon 4 and exons 5-8 
and was cloned into pBluescript II. The rabbit β globin polyadenylation (pA) 
cassette was inserted to the Runx1 cDNA. A neomycin-positive selection 
cassette, expressed under the control of the herpes simplex virus thymidine 
kinase promoter with a 5’ SacII site, was then inserted in reverse orientation 
downstream of the pA cassette. Site-directed mutagenesis was performed to 
introduce mutations into the Runx1 cDNA using a QuickChange site-directed 
mutagenesis kit (Stratagene, La Jolla, CA) and mutagenic primers for F146S (5’-
GAGCGGTAGAGGCAAGAGCTCCACTCTGACCATCACCGTCT-3’), T149A (5’-
AGGCAAGAGCTTCACTCTGGCCATCACCGTCTTTACAAATC-3’), and R174Q 
(5’-CACAGTGGACGGCCCCCAAGAACCCCGAAGACATC-3’). Next, the partial 
Runx1 cDNA-PA-neo was removed by digestion with SacII and cloned into a 
unique SacII site in AML-SS-12, which contained a 10-kb SacI-SpeI fragment of 
mouse genomic DNA flanking Runx1 exon 4 and a diphtheria toxin-negative 
selection cassette that was cloned into the vector pBluescript II SK (Okuda et al., 
1996). The presence of each point mutation and the exon 4-8 sequences in the 
targeting construct were confirmed by sequence analysis. 
 
The resulting targeting vector was linearized with NotI, and 25 µg was 
transfected into the 129/SVEV ES cells (Specialty Media, Phillipsburg, NJ) by 
electroporation. Homologous recombinant clones were identified by Southern 
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blot analysis. Blastocyst injection and breeding of chimeras were performed as 
described previously (Lorsbach et al., 2004). 
 
Yolk sac isolation 
Runx1+/-, Runx1+/F146S, Runx1+/T149A, and Runx1+/T174Q mice were used for timed 
mating. Yolk sacs were isolated at the indicated times and somite pairs were 
counted. Yolk sacs were incubated in collagenase (Sigma) with 20% FCS in PBS 
for 1.5-2 hours at 37oC, passaged through a 20G needle 4-6 times, and washed 
with 10% FSC in PBS twice. The single-cell suspensions of yolk sacs were 
subjected to hematopoietic replating as described above. Hematopoietic colonies 
were counted 4-7 days after replating. 
 
Retrovirus production and infection of differentiated ES cells 
Retroviral infection using the Phoenix packaging cell line was described 
previously (Grignani et al., 1998). Briefly, Phoenix packaging cells were 
maintained in DMEM with 10% FSC and 1% L-Glutamine. On day 0, 3x105 cells 
were plated in one well of a gelatinized 6-well plate. On day 1, Phoenix cells 
were transfected with 3 μg of MSCV-IRES-GFP (control), MSCV-RUNX1-IRES-
GFP, MSCV-GATA1-IRES-GFP, or MSCV-EKLF-IRES-GFP using FuGene 6 
(Roche). The medium was changed 18-24 hours later. The transfected cells were 
then grown at 32oC for 24 hours, and the medium containing viral particles was 
collected and filtered through a 0.45 μm filter before use. Runx1-/- and iRUNX1 
ES cells were differentiated on OP9 cells for 3 days and infected with MSCV-
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IRES-GFP (control), MSCV-RUNX1-IRES-GFP, MSCV-GATA1-IRES-GFP, or 
MSCV-EKLF-IRES-GFP viral supernatants in the presence of polybrene (7.5 
μg/ml). Dox (1.0 μg/ml) was added to iRUNX1 cells on day 3 of differentiation. 
The cells were collected on day 4 by dissociation in trypsin for EryP replating. 
 
Gene expression analysis 
RNA preparation and cDNA generation were described previously (Lugus et al., 
2007; Park et al., 2004). qRT-PCR reactions were performed in duplicate or 
triplicate. Primer sequences utilized in this study are described in Supplementary 
Table 1. 
 
GeneChip analysis 
J1, Runx1-/-, iRUNX1, and iRUNX1+Dox EB cells were differentiated in serum. 
Dox was added on day 3 of EB formation, and cells were collected on day 4. 
Total RNA was purified using TRIzol (Invitrogen, CA), following the 
manufacturer’s protocol. Aliquots of 3 μg of total RNA were subjected to 
GeneChip® Mouse Genome 430 2.0 Array (Affymetrix). GeneChip results were 
analyzed in dChip (Li and Wong, 2001; Zhong et al., 2003). Differences of gene 
expression were determined by applying a 90% confidence interval of >1.4-fold 
and above and using a baseline to experimental intensity difference of >100. 
 
Flow cytometry 
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FACS analysis has been described previously (Ma et al., 2008; Park et al., 2004). 
Briefly, EBs were collected and dissociated in 7.5 mM EDTA in PBS for 1 minute 
at 37oC. Cells were immediately resuspended in washing/staining buffer (4% 
FSC in PBS) and passaged through a 20G needle 5-7 times. 5x105 cells were 
incubated with anti-Flk-1-phycoerythrin (Flk-1-PE, Pharmingen, 1:200 dilution) for 
15 minutes at 4oC in the dark, washed three times, and analyzed using a Becton-
Dickinson FACS Caliber. FACS data was analyzed with CellQuest software 
(Becton-Dickinson). For Ter119 detection in E10.5 embryos, embryo propers and 
yolk sacs were incubated for 90 minutes at 37°C in 0.1% collagenase (Sigma-
Aldrich, St Louis, MO) with 20% fetal bovine serum in phosphate-buffered saline 
(PBS), and were separated into single-cell suspension by passing through 20-
gauge syringes. The resulting suspension cells were stained with FITC-
conjugated Ter119 antibodies (eBioscience, San Diego, CA), and analyzed by 
FACS. The absolute Ter119+ cell number is equal to the total cell number from 
the embryo proper or the yolk sac multiplied by the percentage of Ter119+ cells 
analyzed by FACS. 
 
Yolk sac benzidine staining 
Yolk sacs were fixed in 1 mL 0.2% benzidine solution, which was prepared by 
dissolving 100mg of bezidine dihydrochloride (Sigma) in 50mL of 0.5% acetic 
acid at room temperature for 15 minutes. Next, 20μl of 30% H2O2 was added to 
the tissue and incubated for 5-15 minutes at room temperature. Stained yolk 
sacs were photographed by light microscopy. 
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 Statistics 
The results of hematopoietic replating, qRT-PCR, FACS analysis were analyzed 
by Student’s t test. P < 0.05 was considered statistically significant. 
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Results 
Enforced RUNX1 expression in EBs suppresses primitive erythroid 
progenitor formation 
To assess if Runx1 has a role in EryP development, we first examined EryP 
formation and Runx1 expression during ES differentiation. Specifically, A2Lox ES 
cells, a derivative of E14Tg2a ES cells (Iacovino et al., 2009) were differentiated 
in serum-containing media. These in vitro differentiated ES cells, termed 
embryoid bodies (EB), were analyzed from day 0 to 7 for EryP progenitors and 
Runx1 expression. As in the developing embryo, EryP progenitors appeared 
within a very short window of time in the ES/EB system. EryP progenitors were 
not detected until day 3 of differentiation, rapidly increased by day 4, and sharply 
diminished thereafter (Figure 1.2-1A). Thus, EryP progenitor formation and/or 
proliferation occur between days 3 and 4 during EB development. In EBs, Runx1 
expression was detected starting from day 3, rapidly increased and reached a 
plateau after day 4 (Figure 1.2-1B). Initial analyses suggested that the onset of 
Runx1 expression coincided with the EryP emergence and that high levels of 
Runx1 expression were sustained when EryP progenitors were no longer 
produced in later time points (≥days 5) during EB development.  
 
To evaluate the role of Runx1 in primitive erythropoiesis, we employed an 
inducible ES cell system (Kyba et al., 2002). To this end, we generated inducible 
RUNX1 (iRUNX1) ES cells by targeting the tet-responsive locus of A2Lox ES 
cells with the full length mouse Runx1 cDNA (amino acid residues 1-451), which 
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was fused to a FLAG tag at the 5’ end (Figure 1.2-1C). After the correct targeting 
event was validated by a tet-responsive locus/cDNA vector-specific PCR (not 
shown), inducible Runx1 expression was verified by adding doxycycline (Dox) to 
differentiating ES cells. Specifically, iRUNX1 ES cells were differentiated in 
serum and treated with various concentrations of Dox on day 3, at which time 
point, EryP progenitors are rapidly emerging. Day 4 EB cells were harvested and 
subjected to Western blot analyses using anti-FLAG tag antibody. Exogenous 
RUNX1 was detectable in day 4 EBs with Dox concentrations as low as 0.03 
μg/ml (Figure 1.2-1D). The protein analyses were corroborated by qRT-PCR of 
Runx1 expression, which showed that Dox-treated iRUNX1 EB cells had 
approximately 3- fold (0.01 μg/ml Dox) to 11-fold (≥1 μg/ml Dox) induction of 
Runx1 mRNA expression compared to non-induced cells (Figure 1.2-1E). To 
determine the effect of enforced Runx1 expression on EryP, iRUNX1 ES cells 
were differentiated in serum. Exogenous RUNX1 was induced from day 3 by 
adding Dox, and day 4 EB cells were subjected to EryP replating. The number of 
EryP colonies generated was significantly decreased by about 50%-70% when 
Dox (≥1 μg/ml) was added to EBs compared to -Dox controls or when Dox was 
added at low concentrations (≤0.03 μg/ml) (Figure 1.2-1F, not shown). No 
notable differences were observed in proliferation and/or apoptosis between Dox 
treated versus non-treated EB cells, as judged by Annexin V staining or viable 
cell count (not shown). Our result showed that high level of Runx1 expression 
between days 3 and day 4 during EB differentiation has suppressive effect on 
primitive erythroid progenitor formation.  
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 Runx1 is required for optimal primitive hematopoiesis 
Previous studies suggested that Runx1 null mice did not have defects in primitive 
erythropoiesis. However, quantitative analyses on EryP were not performed in 
these studies (Okuda et al., 1996; Wang et al., 1996). In light of the findings that 
EryP progenitor formation was sensitive to awe determined if EryP progenitor 
number or the kinetics of EryP development could be altered in the absence of 
Runx1. To this end, Runx1+/+, Runx1+/-, and Runx1-/- ES cells were differentiated 
in serum, collected from day 3 to day 7, and subjected to EryP replating. 
Unexpectedly, we saw a great reduction in EryP colony number from Runx1-/- EB 
cells at all time points (Figure 1.2-2A). When day 2.75 EB cells were collected 
and subjected to blast colony replating (Faloon et al., 2000), we observed a 
significantly reduced number of blast colonies, compared to Runx1+/- and 
Runx1+/+ controls (Supplementary Figure 1.2-1A). However, we did not detect 
any changes in the frequency or kinetic changes in FLK-1 expression in EB 
development (Supplementary Figure 1.2-1B). This suggested that Runx1 is 
required downstream of Flk1 mesoderm. To verify the essential role of Runx1 in 
definitive hematopoiesis, Runx1+/+, Runx1+/-, and Runx1-/- ES cells were 
differentiated in serum for six days, and day 6 EBs were subjected to definitive 
and myeloid progenitor replatings. No hematopoietic colonies were generated 
from Runx1-/- EBs (Supplementary Figure 1.2-2A, B). This result is consistent 
with the phenotype of the Runx1 knock-out embryos that have no definitive 
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hematopoiesis (Okuda et al., 1996; Wang et al., 1996). Collectively, Runx1 
clearly plays a role in regulating normal primitive hematopoiesis.  
 
To further investigate the role of Runx1 in primitive hematopoiesis, we examined 
EryP from Runx1-/- yolk sacs. Runx1+/- mice were generated as previously 
described and were used for establishing timed matings (Okuda et al., 1996). 
Consistent with previous studies, E9.5-E10.5 Runx1-/- embryos did not display 
any overt phenotypic defects and were similar in gross morphology to +/- or wild 
type controls (Supplementary Figure 1.2-3A and not shown). Moreover, E10.5 
Runx1-/- embryos showed similar benzidine staining pattern compared to +/- or 
+/+ embryos (Supplementary Figure 1.2-3B). Ter119+ cells were readily present 
within E10.5 Runx1-/- embryos, although the absolute number of Ter119+ cells 
was slightly less compared to +/- or +/+ embryos (Supplementary Figure 1.2-3C). 
Despite the seemingly normal presence of EryP cells, when E8.5 Runx1 +/+, +/- 
and -/- embryos were analyzed, a significantly reduced number of primitive 
erythroid colonies was obtained from E8.5 Runx1-/- yolk sacs compared to 
littermate controls (Figure 1.2-2B). No definitive erythroid or myeloid colonies 
were generated when Runx1-/- yolk sacs from later time points were analyzed, 
confirming that Runx1 was required for definitive hematopoietic development 
(data not shown). This suggests that even though the generation of EryP 
progenitor was greatly compromised in Runx1-/- embryos, the remaining EryP 
progenitors generated were sufficient for maintaining and providing the integrity 
of the developing embryo until definitive hematopoiesis is required. 
 47
 DNA binding and CBFβ interaction of Runx1 is required for normal 
primitive hematopoiesis 
DNA binding and CBFβ interaction are critical for proper RUNX1 function. Based 
on the current structural and biochemical studies, mutations of the Runt domain 
can be classified into three groups: mutations that interrupt DNA binding ability 
(i.e. R174Q), mutations that disrupt CBFβ binding (i.e. T149A), and mutations 
that cause incorrect folding of the Runt domain (i.e. F146S), resulting in the loss 
of DNA and CBFβ binding (Matheny et al., 2007; Nagata and Werner, 2001). To 
determine whether RUNX1 DNA or CBFβ binding is required for primitive 
hematopoiesis, we examined F146S, T149A and R174Q Runx1 knock-in mutant 
mice. When heterozygous mutant mice were brother-sister mated and the 
resulting pups analyzed at P21, we did not detect any live homozygous animals 
for F146S, T149A, or R174Q Runx1 mutant alleles (Table 1). Next, heterozygous 
mutant mice were used for timed matings, and E8.5 yolk sacs of these mutant 
embryos were subjected to EryP replating. Somite pairs were counted while 
dissecting the embryos to ensure that they were at similar developmental stages. 
The number of EryP colonies obtained from Runx1F146S/F146S homozygous mutant 
animals was significantly less, compared to their littermate controls (Figure 1.2-
2C). The reduction level in the number of EryP colonies from the Runx1F146S/F146S 
yolk sacs was similar to that from the Runx1-/- yolk sacs. Runx1T149/T149 or the 
Runx1R174Q/R174Q yolk sacs also produced less EryP progenitors, however, the 
number of EryP colonies generated from these animals was higher than that from 
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the Runx1F146S/F146S or Runx1-/- yolk sacs (Figure 1.2-2D, E). The results 
demonstrate that the ability of Runx1 to interact with CBFβ and bind DNA are 
required for its normal role in primitive hematopoiesis, suggesting that 
components of the Runx1 transcriptional network are important for the normal 
development, proliferation and survival of primitive erythroid cells.  
 
Common erythroid genes are downregulated in Runx1 deficient as well as 
in RUNX1 enforced EBs  
To understand molecular mechanisms by which Runx1 regulates primitive 
hematopoiesis, we performed global gene expression analyses of in vitro 
differentiated Runx1+/+, Runx1-/- and iRUNX1±Dox EBs. Dox was treated from 
days 3-4 at 1μg/ml. RNA samples were subjected to Affymetirx GeneChip® 
Mouse Genome 430 2.0 microarray analyses. GeneChip results were analyzed 
using dChip. We identified that 296 genes were reduced in the Runx1-/- EBs, 
compared to Runx1+/+ EBs, by more than 1.4 fold and that 1219 genes were 
decreased in Dox treated iRUNX1 EBs compared to -Dox controls. Among the 
down-regulated genes in Runx1-/- and RUNX1 enforced EBs, hematopoietic-
related genes were selected and listed in Table 2.  
 
Upon examining the gene expression profile, we noticed several patterns 
associated with Runx1 deficiency and Runx1 overexpression. First, there were 
genes that were downregulated in Dox treated cells but not in Runx1-/- EBs. 
These included Lmo2 and Scl. Recently, Scl has been reported to be upstream 
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of Runx1 (Landry et al., 2008; Nottingham et al., 2007). Second, we found genes 
that were downregulated in both Runx1-/- and enforced RUNX1 EB cells. These 
included Hbb-y and Hba-a1 as well as several transcription factors including 
Gata1, Eklf and cMyb. This category of genes could be Runx1 dosage sensitive 
downstream targets. Third, several genes, including Eraf and glycophorin A 
(Gypa), were greatly downregulated in Runx1-/- EBs, while no significant changes 
were observed in Dox treated iRUNX1 EB cells.  
 
To confirm gene chip analyses, we analyzed day 4 EB cells from Runx1+/+, 
Runx1-/- and iRunx1±Dox by qRT-PCR analyses. Such analyses confirmed that 
Gata1, Eklf and cMyb were downregulated in Runx1-/- as well as Runx1 
overexpressed EBs (Figure 1.2-3A, B). The results were consistent with the 
interpretation that Runx1 deficiency or enforced RUNX1 results in down-
regulation of Gata1 and Eklf expression, which in turn affects optimal EryP 
progenitor formation.  
 
To establish that Runx1 is upstream of Gata1 and/or Eklf in EryP development, 
we first determined whether Runx1 could rescue EryP defects in Runx1-/- ES 
cells. Specifically, Runx1-/- ES cells were differentiated on OP9 cells for 3 days 
and then infected with MSCV-RUNX1 virus for an additional day. Day 4 
differentiated cells were harvested and analyzed for EryP. Runx1-/- cells infected 
with MSCV-RUNX1 virus generated an increased number of EryP colonies 
compared to Runx1-/- cells infected with GFP control virus (Figure 1.2-3C). Next, 
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we tested whether Gata1 and/or Eklf could rescue EryP defects observed in 
Runx1-/- or Dox treated iRunx1 EB cells. To this end, Runx1-/- and iRUNX1 ES 
cells were differentiated on OP9 cells for 3 days, infected with MSCV-GATA1 
and/or the MSCV-EKLF virus for an additional day. Dox was added to iRUNX1 
differentiating ES cells on day 3. Day 4 differentiated cells were harvested and 
analyzed for EryP. Runx1-/- differentiated cells that were infected with MSCV-
GATA1 or with MSCV-EKLF virus generated an increased number of EryP 
colonies compared to control retrovirus-infected cells (Figure 1.2-3C). Moreover, 
MSCV-GATA1 or the MSCV-EKLF virus also partially rescued EryP defects 
observed in Dox treated iRUNX1 cells (Figure 1.2-3D). We did not observe any 
obvious additive effects between Gata1 and Eklf.  
 
TGFβ1 suppresses primitive hematopoiesis 
We previously demonstrated an inhibitory role for TGFβ1 in hematopoietic 
development in the ES/EB system (Park et al., 2004). To further elucidate 
signaling pathways that might regulate EryP generation, we tested various 
pharmacological inhibitors known to affect hematopoietic differentiation in the 
ES/EB system. As the window of time between days 3 and 4 is critical for EryP 
progenitor formation and/or expansion, we added various inhibitors on day 3 and 
analyzed day 4 EBs for EryP colonies. Of the factors tested, TGFβ1 inhibited 
EryP progenitor formation. Meanwhile, inhibition of BMP (noggin), Notch (DAPT, 
gamma-secretase inhibitor N-S-phenyl-glycine-t-butylester) or Hedgehog 
(cyclopamine) signaling did not affect the number of EryP colonies formed 
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(Figure 1.2-4A and Supplementary Figure 1.2-4A). As the inhibitory effect of 
TGFβ1 on EryP could be serum dependent, we also performed ES differentiation 
in serum free conditions by adding BMP4 and VEGF (Park et al., 2004). TGFβ1 
inhibitory role was also observed in serum free conditions (Figure 1.2-4C). 
Importantly, Runx1 expression was increased when TGFβ1 was added to the 
culture (Figure 1.2-4B and 1.2-4D). Runx1 expression was increased even 
greater in serum free conditions (Figure 1.2-4D). We did not observe substantial 
changes of Runx1 expression among other inhibitor treated EBs (Supplementary 
Figure 1.2-4B).  
 
To determine if the potential inverse relationship between TGFβ1 and Runx1 
expression in EryP formation was relevant, we next analyzed Tgfβ1-/- ES cells. 
As serum might contain TGFβ1, we applied serum free conditions in generating 
EryP by adding BMP-4 and VEGF. In serum free conditions, day 5 EB cells 
generated prominent number of EryP colonies (Figure 1.2-4E). Tgfβ1-/- ES cells 
generated a greater number of EryP colonies compared to +/+ or +/- ES cells 
(Figure 1.2-4E and not shown). Importantly, Runx1 expression levels in day 4 or 
5 Tgfβ1-/- EB cells were significantly lower compared to Tgfβ1+/- EB cells (Figure 
1.2-4F).  
 
TGFβ1 suppresses primitive erythropoiesis through ALK5 
TGFβ1 can bind either type I receptor, ALK1 or ALK5, to activate down-stream 
SMAD1/5/8 or SMAD2/3, respectively (Goumans et al., 2002; Lux et al., 1999; 
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Oh et al., 2000; Shi and Massague, 2003). In order to determine which type I 
TGFβ1 receptor is responsible for the suppression of EryP, we first examined 
Alk1 and Alk5 expression levels in maturing EryP cells. Specifically, wild-type ES 
cells were differentiated in serum, and day 4 EB cells were subjected to EryP 
replating. EryP colonies were collected two and three days after replating and 
subjected to qRT-PCR analysis. Gene expression analyses of day 2 and day 3 
EryP cells demonstrated that Alk5, not Alk1, was highly expressed in 
differentiating EryP cells (Figure 1.2-5A). 
 
Next, we used the ES/EB system of Alk1 and Alk5 null ES cell lines to further 
dissect the axis of the TGFβ1 signaling in primitive hematopoiesis (Larsson et al., 
2001; Oh et al., 2000). Specifically, we differentiated Alk1-/- and Alk5-/- ES cells, 
along with their controls, in serum for 4 days, and EB cells were subjected to 
EryP replating. As shown in Figure 1.2-5B, Alk5-/- EBs generated a significantly 
higher number of EryP colonies compared to Alk5+/+ EBs. However, the number 
of EryP colonies generated from Alk1+/- vs Alk1-/- was similar (Figure 1.2-5B). To 
further examine the TGFβ1-ALK5 axis in EryP development, we treated wild-type 
EBs in serum with SB431542 on day 3 (Inman et al., 2002), which inhibits the 
interaction between TGFβ1 and ALK5, not ALK1. SB431542 treated EBs 
generated more EryP colonies than non-treated EBs (Supplementary Figure 1.2-
5). To eliminate the possibility that TGFβ1 could use additional receptors in EryP 
suppression, we used serum-free differentiation conditions to test whether EryP 
colony numbers could be further decreased with TGFβ1 treatment in Alk5-/- EBs. 
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We subjected Alk1+/-, Alk1-/-, Alk5+/+, and Alk5-/- ES cells to serum-free 
differentiation with BMP4 and VEGF. TGFβ1 was added on day 3, and day 4 EB 
cells were analyzed for EryP colony formation. The results showed that Alk5-/- 
EBs had similar EryP colonies regardless of TGFβ1 treatment, whereas Alk1-/- 
EBs generated less number of EryP colonies when treated with TGFβ1 (Figure 
1.2-5C). Runx1 was expressed at much lower levels in day 4 Alk5-/- EBs 
compared to Alk5+/+ EBs (Figure 1.2-5D). In addition, Runx1 expression levels 
were similar in Alk1-/- and controls. However, both Gata1 and Eklf were 
downregulated by TGFβ1, but upregulated in Alk5-/- EBs (Supplementary Figure 
1.2-6A, B). Collectively, these data indicated that TGFβ1 through ALK5, rather 
than through ALK1, could modulate Runx1 expression to suppress EryP 
progenitor development and/or proliferation. 
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Discussion 
The expression of Runx1 is among the earliest molecular markers for blood 
formation in Xenopus, and expression of a truncated Xaml protein can inhibit 
primitive hematopoiesis (Tracey et al., 1998). Studies in zebrafish demonstrate 
that runx1 is involved in both primitive and definitive hematopoiesis (Kalev-
Zylinska et al., 2002). In mice, Runx1 expression can be first detected in 
extraembryonic mesodermal cells at E7.25 and in primitive erythrocytes of the 
yolk sac blood islands at E8.0-E8.5 (Lacaud et al., 2002; North et al., 1999). 
Herein, we demonstrate that yolk sacs from Runx1 mutant mice (Runx1-/-), 
harboring homozygous deletion of the Runt domain encoding exon 4, have 
defects in primitive hematopoiesis. The defect was at the progenitor level, as the 
number of EryP progenitors was greatly decreased in these mice. However, we 
could still detect Ter119+ cells in yolk sacs from the Runx1-/- embryos at E10.5, 
at a level, which was similar to that of wild type controls. Benzidine staining levels 
were also comparable between wild type and Runx1-/- embryos at E10.5. 
Although we have not examined mature EryP cell morphology, Yokomizo et al. 
recently showed that circulating primitive erythrocytes from Runx1-/- embryos, 
which also delete exon 4, were morphologically defective (Yokomizo et al., 2008). 
We suggest that the residual EryP precursors present in Runx1-/- embryos could 
still produce mature primitive erythroid cells, which could deliver adequate 
oxygen to sustain the survival of the knockout embryos during the early 
embryogenesis. In adult, only a small fraction of hematopoietic stem cells (HSCs) 
generate mature blood cells at a given time. Thus, to guarantee production of 
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EryP cells, it is possible that developing embryos reserve a large number of EryP 
progenitors, which exceed the amount that the embryo actually requires. Future 
studies to determine whether all EryP progenitors participate in generating 
mature EryP cells are warranted.  Alternatively, Yokomizo et al. showed that the 
number of EryP progenitors present within the Runx1-/- embryos, was similar to 
that from +/- control embryos (Yokomizo et al., 2008). As the authors in this study 
used the whole embryo for EryP replating, this study suggests an intra-embryonic 
generation of EryP progenitors in the absence of Runx1. Previous studies 
support the notion that Runx1 dosage could modulate hematopoietic progenitor 
production from different embryonic tissues. Specifically, the spatial and temporal 
appearance of hematopoietic stem cells (HSCs) in the yolk sac and AGM is 
sensitive to Runx1 dosage, as HSCs appear prematurely in the E10 Runx1+/− 
yolk sac and there was a premature termination of HSC activity in the Runx1+/− 
AGM explant culture (Cai et al., 2000). Studies on whether AGM can generate 
EryP progenitors when Runx1 mediated definitive hematopoietic program is 
absent are warranted. 
 
Intriguingly, in contrast to Runx1-/- mice, which delete exon 4, that we used in this 
study, another Runx1 mutant mouse line (North et al., 1999), which harbors lacZ 
in place of exon 7 and 8, or Runx1LacZ/LacZ ES cells do not appear to have EryP 
defects (Lacaud et al., 2002). This suggests that a functional Runt domain is 
critical for primitive EryP development. Indeed, by utilizing Runx1 mutant mice 
homozygous for DNA, CBFβ as well as DNA and CBFβ-binding domain, we 
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show that both DNA and CBFβ binding are required for optimal EryP 
development. 
 
While EryP progenitors in the yolk sac were sub-optimally generated in the 
absence of Runx1, we also found that a high level of Runx1 expression in the 
ES/EB system was able to repress EryP progenitor formation and/or expansion. 
Runx1 can either activate or repress target genes by interacting with co-activator 
or co-repressor, respectively (Kitabayashi et al., 1998; Lutterbach et al., 2000). 
Although we could not determine the interaction between RUNX1 and mSin3A 
co-repressor in the ES/EB system (data not shown), we cannot rule out the 
possibility that such RUNX1 suppression of EryP was due to RUNX1 interaction 
with other co-repressors. Currently available studies support the notion that 
Runx1 dosage is critical for proper hematopoiesis. As discussed, hematopoietic 
stem cell and hematopoietic progenitor generation were sensitive to Runx1 
dosage (Cai et al., 2000; Mukouyama et al., 2000; North et al., 2002). 
Additionally, an extra copy of Runx1 on chromosome 21 could potentially be 
responsible for predisposing Down’s syndrome children to increased risk of 
developing leukemia (Dufresne-Zacharia et al., 1994; Gurbuxani et al., 2004). 
 
We provide evidence that Gata1 and Eklf are genetically downstream of Runx1 in 
EryP development. Both genes were downregulated by enforced Runx1 
expression and in Runx1-/- EBs compared to wild type controls. Moreover, both 
Gata1 and Eklf could partially rescue EryP defects seen in induced Runx1 and 
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Runx1-/- ES cells. Gata1 plays a critical role in the regulation of erythroid-specific 
genes in both primitive and definitive erythroid cells. Gata1 is highly expressed in 
both primitive and definitive erythroid progenitors (Whitelaw et al., 1990). Gata1 
knockout ES cells fail to generate EryP progenitors. EryD progenitors fail to 
mature in the absence of GATA1 (Weiss et al., 1994). Gata1 knockout ES cells 
contribute to all non-hematopoietic tissues but fail to give rise to mature red blood 
cell in chimaeric mice (Pevny et al., 1991). Moreover, GATA1 has been shown to 
bind to the promoters of many erythroid cell-specific genes including the β globin 
locus control region (βLCR) (Cantor and Orkin, 2002; Palstra et al., 2008; Vakoc 
et al., 2005). Eklf was originally thought to mainly regulate the adult β-globin 
genes. However, recent studies have shown that EKLF also regulates embryonic 
globin expression (Basu et al., 2007; Hodge et al., 2006). Eklf-/- embryos have 
nucleated primitive erythroid cells with an abnormal morphology (Drissen et al., 
2005). In Runx1-/- EBs, embryonic globin expression was significantly lower 
compared to wild-type controls. However, we failed to show direct binding of 
RUNX1 to the Gata1, Eklf, or βLCR region by chromatin immuno-precipitation 
(ChIP) analysis (data not shown). We conclude that low embryonic globin 
expressions in induced Runx1 and Runx1-/- EBs could be due to the suboptimal 
expression of Gata1 and Eklf. 
 
TGFβ1-/-, TgfβrII-/-, and Alk5-/- mice all display anemia and severe defects in 
angiogenesis in the yolk sac (Dickson et al., 1995; Larsson et al., 2001; Oshima 
et al., 1996). Despite the severe anemia, Alk5-/- yolk sacs contained a higher 
 58
number of erythroid progenitors, demonstrating that anemia seen in these mice is 
secondary to the angiogenic defects. Intriguingly, TGFβ1-/- yolk sacs appeared to 
contain significant numbers of circulating non-hemoglobinized blood cells 
(Dickson et al., 1995). Herein, we demonstrate that TGFβ1 could up-regulate 
Runx1 and suppress EryP progenitor formation. We determined that ALK5 is the 
major TGFβ type I receptor in primitive erythroid cells. Both TGFβ1-/- and Alk5-/- 
ES cells generated a higher number of EryP colonies. It is worth pointing out that 
the increase in Runx1 expression level by TGFβ1 treatment in serum was at best 
1.5-2 fold. In our studies, TGFβ1 suppressed a broader range of hematopoietic-
related transcriptional factors, such as Scl, Gata1, Eklf, c-myb and Lmo2. 
Therefore, we suggest that TGFβ1 could inhibit EryP development through many 
genetic pathways, one of which could be Runx1. Alternatively, previous studies 
have established that TGFβ growth factors can modulate RUNX protein stability 
and/or activity. Specifically, TGFβ/BMP-activated Smads can interact with RUNX 
and stimulate transcription of RUNX target genes (Hanai et al., 1999; Ito, 2004; 
Miyazono et al., 2004). Moreover, BMP induces differentiation of mesenchymal 
cells into osteoblasts by upregulating the expression of Runx2 and its interaction 
with BMP-activated SMADs (Ito and Miyazono, 2003; Lee et al., 2000; Zhang et 
al., 2000). In hepatic cells (Wildey and Howe, 2009), TGFβ induces Runx1, which 
in turn interacts with FOXO3 to upregulate Bim expression to mediate apoptosis. 
Finally, TGFβ/BMP activate a stress-activated protein kinase p38 (SAPKs) 
(Gallea et al., 2001; Hanafusa et al., 1999). Both the Smad and MAPK pathways 
are essential components of the TGFβ superfamily signaling during osteoblast 
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differentiation (Derynck et al., 2001; Fujii et al., 1999; Gallea et al., 2001; 
Nishimura et al., 1998; Yamamoto et al., 1997) and for Runx2 induction (Lee et 
al., 2002). We suggest that such interaction between TGFβ1 and Runx1 also 
regulates primitive hematopoiesis. Collectively, our studies demonstrate that 
Runx1 dosage is critical for optimal EryP progenitor generation. Potentially, 
TGFβ1 family of factors could be upstream, which can modulate Runx1 levels or 
activity to achieve optimal primitive hematopoiesis. 
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Figure 1.2-1. 
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Figure Legends 
Figure 1.2-1. Enforced RUNX1 expression during ES cell differentiation 
results in reduced EryP progenitors. 
(A and B) A2Lox ES cells were differentiated in serum. EB cells were collected at 
indicated time points for EryP replating (A) and Runx1 expression analysis (B). 
EryP colonies were counted 4-5 days after replating. Runx1 expression was 
analyzed and normalized to Gapdh. Values indicate mean±s.e.m. from three 
independent experiments. 
(C) Schematic of the inducible RUNX1 (iRUNX1) ES cell lines with indicated loci 
containing modifications for production of rtTA and expression of Runx1 cDNA. 
(D) Western blot of the iRUNX1 ES cell lines. iRUNX1 ES cells differentiated in 
serum for three days were treated with the indicated concentrations of Dox for 
one additional day. Cells were collected on day 4 and subjected to SDS-PAGE 
followed by blotting with anti-FLAG and anti-β-actin antibodies. 
(E) iRUNX1 ES cells were differentiated and treated with the indicated 
concentration of Dox on day 3. EB cells were harvested on day 4 for Runx1 
expression analysis by qRT-PCR. Runx1 expression was analyzed and 
normalized to Gapdh. The expression level of Runx1 in untreated cells was 
normalized as 1 and used to determine the Runx1-fold change in Dox-treated 
samples. Values indicate mean±s.e.m. from three independent experiments. 
(F) iRUNX1 ES cells differentiated in serum were treated with Dox at 0.03 μg/ml 
or at 1.0 μg/ml on day 3 and harvested on day 4 for EryP replating. Values 
indicate mean±s.e.m. from three independent experiments; ***p<0.001. 
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Figure 1.2-2. 
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Figure 1.2-2. Runx1 null and Runx1 mutations resulted in decreased 
number of EryP progenitors in yolk sac. 
(A) J1, Runx1+/-, and Runx1-/- ES cells differentiated in serum were harvested for 
EryP progenitor assay on the indicated day. Values are mean±s.e.m. of EryP 
colonies from four independent experiments. 
(B) Primitive erythroid colonies from E8.5 yolk sacs (4-7 somite pair stage) of 
Runx1+/+ (n=9), Runx1+/- (n=13), and Runx1-/- (n=13). 
(C) EryP colonies of Runx1-F146S E8.5 yolk sacs (3-10 somite pair stage). n+/+ = 
5; n+/F146S = 12; nF146S/F146S = 5. 
(D) EryP colonies of Runx1-T149A E8.5 yolk sacs (3-8 somite pair stage). n+/+ = 
8; n+/T149A = 25; nT149A/T149A = 18. 
(E) EryP colonies of Runx1-R174Q E8.5 yolk sacs (3-9 somite pair stage). n+/+ = 
10; n+/R174Q = 16; nR174Q/R174Q = 8. The results show mean±s.e.m. of EryP 
colonies. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 1.2-3. 
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Figure 1.2-3. Gata1 and Eklf rescue decreased EryP progenitor formation in 
Runx1-/- and iRUNX1 EBs. 
(A) J1 and Runx1-/- ES cells were differentiated in serum, and EB cells were 
harvested on day 4. RNA was utilized for qRT-PCR analysis. Gene expressions 
were normalized against Gapdh, and then the ratio of the gene expression 
(Runx1-/-) to gene expression (J1) was determined to generate normalized fold 
change. Values indicate mean±s.e.m. from three independent experiments. 
(B) iRUNX1 ES cells were differentiated in serum, Dox (1.0 μg/ml) was added on 
day3, and EB cells were collected for qRT-PCR on day 4. Gene expressions 
were normalized against Gapdh, and then the normalized fold change was 
determined by calculating the ratio of the +Dox to -Dox. Values indicate 
mean±s.e.m.from two to three independent experiments. 
(C and D) Runx1-/- (C) and iRUNX1 (D) ES cells were differentiated for three 
days on OP9 cells, and cells were infected with MSCV-RUNX1-IRES-GFP, 
MSCV-GATA1-IRES-GFP, or MSCV-EKLF-IRES-GFP viral supernatants. One 
day later, the cells were collected for primitive erythroid replating. For the 
differentiation of iRUNX1 ES cell, Dox was added on day 3. Cells treated with 
MSCV-IRES-GFP viral supernatant were used as controls. Values are mean of 
EryP colonies±s.e.m. from three independent experiments. *p<0.05, **p<0.01, 
***p<0.001. 
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Figure 1.2-4. 
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Figure 1.2-4. TGFβ1 inhibits EryP progenitor formation and induces Runx1 
expression. 
(A and B) A2Lox ES cells were differentiated in serum, TGFβ1 (10 ng/ml) was 
added on day 3, and EB cells were collected on day 4 for EryP replating (A) and 
qRT-PCR (B). Runx1 expression was normalized against Gapdh, and then the 
normalized fold change was determined by calculating the ratio of +TGFβ1 to -
TGFβ1. Values are mean±s.e.m. from three independent experiments. 
(C) TGFβ1 inhibits the number of EryP progenitors in serum free condition. 
A2Lox ES cells were differentiated in serum free (SR) media with BMP4 (5 ng/ml) 
and VEGF (10 ng/ml). TGFβ1 (10 ng/ml) was added on day 3, and day 4 EBs 
cells were collected for EryP replating. Values are mean±s.e.m. from three 
independent experiments. 
(D) TGFβ1 induces Runx1 expression in serum free conditions. A2Lox ES cells 
were differentiated for 2 days in SR and treated with TGFβ1 (10 ng/ml) for two 
more days. Day 4 EBs were harvested for qRT-PCR analysis. Runx1 expression 
was normalized against Gapdh and the ratio of Runx1 quantity (+TGFβ1) to 
Runx1 quantity (SR) was determined to yield normalized fold change. Values are 
mean±s.e.m. from two independent experiments. 
(E and F) Deficiency in TGFβ1 leads to increased EryP colony formation with 
decreased Runx1 expression. Tgfβ1+/- and Tgfβ1-/- ES cells were differentiated in 
serum free (SR) with BMP4 (5 ng/ml) and VEGF (10 ng/ml). Day 4 and day 5 EB 
cells were harvested for EryP replating (E) and Runx1 expression analysis by 
qRT-PCR (F). Runx1 expression was normalized against Gapdh. Values are 
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mean±s.e.m. from three independent experiments. *p<0.05, **p<0.01, ***p 
<0.001. 
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Figure 1.2-5. 
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Figure 1.2-5. Alk5 deficiency generates increased EryP progenitors. 
(A) ALK5 is the major TGFβ type I receptor in developing EryP colonies. A2Lox 
ES cells were differentiated in serum for 4 days and subjected to EryP colony 
assay. EryP cells harvested from 2 days and 3 days after replating were utilized 
for qRT-PCR analyses. Gene expressions were normalized against Gapdh. 
Values are mean±s.e.m. from two independent experiments. 
(B) Alk5-/- EB cells generate increased EryP colonies. Alk1+/-, Alk1-/-, Alk5+/+, and 
Alk5-/- ES cells differentiated in serum for 4 days were used for EryP progenitor 
assays. Values are mean±s.e.m. of EryP colonies from three independent 
experiments. 
(C) TGFβ1 fails to suppress EryP progenitor formation in Alk5-/- EBs. Alk1+/-, 
Alk1-/-, Alk5+/+, and Alk5-/- ES cells differentiated in serum free (SR) with BMP4 (5 
ng/ml) and VEGF (10 ng/ml) were treated with TGFβ1 (10 ng/ml) on day 3 and 
were collected for EryP progenitor assay on day 4. The number of EryP colonies 
in untreated cells was normalized as 1 and used to determine the ratio of the 
EryP colonies in TGFβ1-treated samples. Values are mean±s.e.m. from three 
independent experiments. 
(D) Alk1+/-, Alk1-/-, Alk5+/+, and Alk5-/- EB cells were harvested on day 4 and RNA 
samples were generated for qRT-PCR analyses. Runx1 expression was 
normalized against Gapdh. Values are mean±s.e.m. from three independent 
experiments. 
*p<0.05, **p<0.01, ***p <0.001. 
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Table 1.2-1. Viability of progeny from intercrosses of Runx1m/+ mice 
 
Biochemical Properties* No. (%) of live mice at P21 
DNA binding CBFβ binding +/+ +/m m/m 
F146S - - 169 (40.8) 245 (59.2) 0 
T149A ++ - 53 (32.1) 112 (67.9) 0 
R174Q - ++ 109 (32.6) 225 (67.4) 0 
 
-, loss of function 
++, equivalent to wild-type 
P: postnatal day 
m: mutant allele 
*(Nagata and Werner, 2001) 
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Table 1.2-2. Common erythroid genes were downregulated in Runx1-/- and 
iRUNX1+Dox EBs. 
Microarrary ID EntrezGene ID gene Fold change of Runx1-/-/J1 
Fold change of 
+Dox/-Dox 
1452207_at 17684 Cited2: Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 - -1.80 
1425400_a_at 56222 Cited4: Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4 - -6.43 
1423344_at 13857 Epor: erythropoietin receptor - -1.87 
1452514_a_at 16590 Kit: kit oncogene - -2.44 
1415855_at 17311 Kitl: kit ligand - -2.68 
1450736_a_at 15132 Hbb-bh1: hemoglobin Z, beta-like embryonic chain - -1.95 
1454086_a_at 16909 Lmo2 : LIM domain only 2 - -3.12 *
1449389_at 21349 Tal1: T-cell acute lymphocytic leukemia 1 - -4.77 *
1449232_at 14460 Gata1: GATA binding protein 1 -1.45 -2.27 *
1418600_at 16596 Klf1: Kruppel-like factor 1 (erythroid) -2.00 -3.80 *
1450194_a_at 17863 Myb: myeloblastosis oncogene -1.59 -2.99 *
1436823_x_at 15135 Hbb-y: hemoglobin Y, beta-like embryonic chain -5.88 -5.61 *
1417714_x_at 15122 Hba-a1: hemoglobin alpha, adult chain 1 -2.72 -1.57 
1425643_at 14934 Gypa: glycophorin A -2.35 - 
1449077_at 170812 Eraf: erythroid associated factor -5.90 - 
 
- indicates not applicable 
* gene expression subjected to qRT-PCR analysis 
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Supplementary Figure 1.2-1. 
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Supplementary Figure 1.2-1. Runx1-/- EBs have reduced blast colonies and 
comparable FLK1+ differentiation kinetics compared to wild type EBs by 
FACS analysis. 
(A) J1, Runx1+/- and Runx1-/- ES cells differentiated in serum were collected on 
day 2.75 for blast colony replating. Values are mean±s.e.m. from three 
independent experiments; **p<0.01. 
(B) FACS analyses for FLK1 expression of J1, Runx1+/-, and Runx1-/- EBs. ES 
cells were differentiated in serum, and cells were collected for FLK1+ detection by 
FACS from day 2 to day 5. Values are mean±s.e.m. from three independent 
experiments. 
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Supplementary Figure 1.2-2. 
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Supplementary Figure 1.2-2. Runx1-/- EB cells have no definitive 
hematopoietic colonies. 
J1, Runx1+/-, and Runx1-/- ES cells were differentiated in serum for six days. EB 
cells were harvested for definitive erythroid and myeloid replating. Colonies of 
EryD (A) and Mac (B) were counted 6-7 days after replating. Values are 
mean±s.e.m..from three independent experiments; **p<0.01. EryD: definitive 
erythroid colony, Mac: macrophage colony. 
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Supplementary Figure 1.2-3. 
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Supplementary Figure 1.2-3. E10.5 Runx1-/- embryos have no gross 
abnormalities in blood cell generation. 
(A) Morphology and (B) Benzidine staining of yolk sacs of Runx1+/+,Runx1+/-, and 
Runx1-/- embryos at E10.5. 
(C) FACS analysis on Ter119+ cells of the embryo proper (left) and the yolk sac 
(right) at E10.5. Values indicate mean±s.e.m. of total Ter119+ cells from Runx1+/+ 
(n=1), Runx1+/– (n=4), and Runx1–/– (n=2) embryos. 
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Supplementary Figure 1.2-4. 
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Supplementary Figure 1.2-4. Noggin, DAPT, and cyclopamine do not affect 
EryP progenitor formation and Runx1 expression. 
(A) A2Lox ES cells were differentiated in serum, Noggin (50 ng/ml), DAPT (2 μM 
added 2 times/day), and Cyclopamine (3 μM) were added on day 3 and EB cells 
were collected on day 4 for EryP replating (A) and qRT-PCR (B). Runx1 
expression was normalized against Gapdh. The quantity of Runx1 expression in 
FSC was normalized as 1 and used to determine the Runx1-fold change in 
inhibitor-treated samples. Values indicate mean±s.e.m. of EryP colonies from 
three independent experiments. 
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Supplementary Figure 1.2-5. 
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Supplementary Figure 1.2-5. SB431542 treated EB cells generate increased 
EryP colonies. 
iRUNX1 ES cells differentiated in serum for 3 days were treated with SB431542 
(2 μM) on day 3. Cells were collected on day 4 for EryP replating. EryP colonies 
were counted, and the numbers of EryP colonies in SB431542-treated samples 
were normalized to that of FSC. Values are mean±s.e.m. from three independent 
experiments; **p<0.01. 
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Supplementary Figure 1.2-6. 
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Supplementary Figure 1.2-6. Gata1 and Eklf expressions were decreased in 
TGFβ1 treated EBs but increased in Alk5-/- EBs. 
(A) A2Lox ES cells differentiated in serum were treated with and without TGFβ1 
(10 ng/ml) on day 3. Cells were harvested on day 4 for qRT-PCR. Gene 
expressions were normalized against Gapdh, and then the normalized fold 
change was determined by calculating the ratio of the gene expression (+TGFβ1) 
to gene expression (-TGFβ1). Values are mean±s.e.m. from two to three 
independent experiments. 
(B) Alk1+/-, Alk1-/-, Alk5+/+, and Alk5-/- EB cells were harvested on day 4 for for 
qRT-PCR analyses. Gene expressions were normalized against Gapdh. Values 
are mean±s.e.m. from three independent experiments; **p<0.01, ***p<0.001. 
 
 92
 93
Supplementary Table 1.2-1. Primer sequences for qRT-PCR. 
Gene  Primer Sequence (5’-3’) Source 
Gapdh 
Forward TGGCAAAGTGGAGATTGTTGCC 
Lugus et al., 2007. 
Reverse AAGATGGTGATGGGCTTCCCG 
Runx1 
Forward CTTCCTCTGCTCCGTGCTA 
#Primer 3 
Reverse CTGCCGAGTAGTTTTCATCG 
Gata1 
Forward ATGGAATCCAGACGAGGAAC 
Lugus et al., 2007. 
Reverse CTCCCCACAATTCCCACTAC 
Scl 
Forward CAGCCTGATGCTAAGGCAAG 
Lugus et al., 2007. 
Reverse AGCCAACCTACCATGCACAC 
Eklf 
Forward ATGGGCTGCTGTCGGGATA 
&PrimerBank ID: 6754454a3 
Reverse TCTTAGGTGCCAAAGTTCGCC 
c-myb 
Forward GAGCACCCAACTGTTCTCG 
PrimerBank ID: 19526473a1 
Reverse CACCAGGGGCCTGTTCTTAG 
Lmo2 
Forward AGGAGAGACTATCTCAGGCTTTT
PrimerBank ID: 6678702a3 
Reverse TTGAAACACTCCAGGTGATACAC
Hbb-Y 
Forward TGGCCTGTGGAGTAAGGTCAA 
PrimerBank ID: 6680177a1 
Reverse GAAGCAGAGGACAAGTTCCCA 
Alk1 
Forward GGGCCTTTTGATGCTGTCG 
PrimerBank ID: 6752958a1 
Reverse TGGCAGAATGGTCTCTTGCAG 
Alk5 
Forward TCTGCATTGCACTTATGCTGA 
PrimerBank ID: 2853637a1 
Reverse AAAGGGCGATCTAGTGATGGA 
 
#Primer 3: http://biotools.umassmed.edu/bioapps/primer3_www.cgi 
&Primerbank: http://pga.mgh.harvard.edu/primerbank/ 
 
  
 
 
 
 
 
Chapter 1.3 
Conclusion and Future Directions 
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Summary of Chapter One 
 During embryonic development, the appearance of red blood cells in the 
yolk sac marks the onset of hematopoiesis, known as primitive hematopoiesis. 
Primitive hematopoietic progenitors emerge exclusively in the yolk sac and are 
characterized by their transient nature. While the primitive hematopoiesis in the 
yolk sac declines, definitive hematopoiesis will begin to emerge in the yolk sac 
and/or in the embryo proper to take over blood cell production. The mechanisms 
regulating the transition from primitive to definitive hematopoiesis remain unclear. 
Runx1 has been reported to be essential for the establishment of definitive 
hematopoiesis, but its expression can also be detected in the yolk sac blood 
islands where primitive erythroid (EryP) progenitors emerge, suggesting that 
Runx1 might also play a role in primitive hematopoiesis. In chapter one, we have 
revealed novel roles of Runx1 in primitive hematopoietic development, based on 
studies utilizing the embryonic stem (ES) cell differentiation system and Runx1 
mutant mice. We have found that inducing Runx1 expression in the in vitro 
differentiation model of embryonic stem (ES) cells results in a decrease in EryP 
progenitor formation. A possible mechanism for this is related to the activity of 
transforming growth factor beta-1 (TGFβ1). We have demonstrated that TGFβ1 
inhibits EryP progenitor formation and upregulates Runx1 expression. Tgfβ1-/- ES 
cells generate increased numbers of EryP progenitors with decreased Runx1 
expression levels. In addition, it was determined that ALK5 is the major type-I 
TGFβ1 receptor in EryP cells and Alk5-deficient ES cells produce higher 
numbers of EryP progenitors, relative to wild-type. Surprisingly, both Runx1 null 
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animals and Runx1-deficient ES cells give rise to reduced numbers of EryP 
progenitors. However, despite generating fewer EryP progenitors during primitive 
hematopoiesis, Runx1-deficient mice can still survive during development until 
definitive hematopoiesis takes over blood formation. DNA binding and CBFβ 
interaction of RUNX1 are needed for optimal generation of EryP progenitors in 
vivo. The decreased EryP progenitors in both Runx1 null and overexpression 
systems coincide with decreased expressions of the transcription factors, Gata1 
and Eklf, and introduction of Gata1 or Eklf partially rescue the EryP defects in 
both systems. Taken together, these studies suggest that RUNX1, likely in 
concert with TGFβ1, plays a critical role in the regulation of primitive 
hematopoiesis. 
 
Possible Mechanisms for Runx1-Mediated Suppression of EryP 
Development 
Our studies have demonstrated that overexpression of Runx1 between day 
3 and day 4 of EB differentiation suppresses primitive erythroid progenitor 
formation in a dose-dependent manner. This observation leads to the intriguing 
question of how Runx1 inhibits EryP generation. One possibility is that RUNX1 
could directly modulate the expression of genes that are critical for EryP 
formation or development. The reduction of EryP progenitors coincides with the 
downregulation of multiple hematopoietic-related genes. One of the most 
downregulated genes is Hbb-y-globin (hemoglobin Y, beta-like embryonic chain), 
which reflects significantly reduced EryP levels. The β locus control region (βLCR) 
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is the most important regulatory element in the regulation of the expression of β-
globin proteins (Noordermeer and de Laat, 2008). One hypothesis is that RUNX1 
can regulate Hbb-y-globin expression by directly binding to the βLCR locus. 
However, RUNX1 binding to the βLCR region has not been detected by 
chromatin immunoprecipitation (ChIP) analysis (not shown). Therefore, the data 
suggest that RUNX1 more likely inhibits Hbb-y-globin expression through an 
indirect mechanism.   
Gata1 and Eklf have been shown to be involved in both primitive and 
definitive erythropoiesis. Both Gata1 and Eklf expression are decreased by 
induced Runx1 expression. Rescue of either Gata1 or Eklf by retroviral infection 
can partially reverse EryP defects seen in induced Runx1 EB cells, suggesting 
that Gata1 and Eklf might be directly regulated by Runx1. We have identified two 
conserved Runx1 binding sites upstream of the transcriptional start sites of 
Gata1 and one binging site upstream from the start site of Eklf. ChIP analysis did 
not reveal any direct binding of RUNX1 to these predicted sites (not shown) but 
these computationally-predicted binding sites may not include all of the biological 
RUNX1 binding sites in Gata1 and Eklf locus. Based on this possibility, a 
genome-wide screening of RUNX1 binding targets in induced Runx1 EBs is 
warranted. Chromatin immunoprecipitation-sequencing (ChIP-Seq) technology is 
well-suited for this purpose (Mikkelsen et al., 2007). Comparing the microarray 
data that is already on hand with the results from ChIP-Seq would provide 
valuable information about how RUNX1 carries out its inhibitory role in EryP 
progenitor formation.  
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 Another possible mechanism by which RUNX1 may negatively regulate 
EryP generation would involve binding partners of RUNX1. RUNX1 can inhibit or 
activate target genes by interacting with transcriptional co-repressors or co-
activators. For example, RUNX1 can interact cooperatively with p300, a 
transcriptional co-activator, to promote differentiation of a myeloid precursor cell 
line into mature neutrophils in response to granulocyte colony-stimulating factor 
(Kitabayashi et al., 1998). Conversely, RUNX1 interacts with the mSin3A co-
repressor to repress p21Waf1/Cip11 promoter activity in NIH3T3 cells or to repress 
c-Mpl expression in hematopoietic progenitor cells (Lutterbach et al., 2000; Satoh 
et al., 2008). We have tested whether RUNX1 can interact with mSin3A to 
suppress EryP progenitor formation. We could not co-immunoprecipitate RUNX1 
and mSin3A from induced Runx1 EB cells, suggesting that Runx1 suppression of 
EryP progenitors may be not due to the interaction of RUNX1 and mSin3A in the 
ES/EB system. The suppression could, however, be due to RUNX1 interaction 
with other co-repressors such as Groucho/TLE and HDAC (histone 
deacetylase)(Durst and Hiebert, 2004; Durst et al., 2003; Imai et al., 1998). In 
support of this possibility, RUNX2, another member of the RUNX family, has 
been shown to interact with HDAC6, and the deacetylase activity of HDAC6 has 
been shown to repress RUNX2 target genes in osteoblast lineage cell lines 
(Westendorf et al., 2002). Additional studies, based on proteomics, designed to 
identify specific binding partners or co-repressors of RUNX1 in the ES/EB system 
should be undertaken in the future to clarify this mechanism. 
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The Relationship between TGFβ1 and Runx1 in Primitive Hematopoiesis 
 TGFβ acts as a negative regulator of the proliferation of adult 
hematopoietic progenitor cells in vitro (Keller et al., 1990; Ottmann and Pelus, 
1988). Previous studies found that Alk5-/- yolk sac cells generate significant 
increased number of erythroid colony-forming cells, suggesting TGFβ signaling 
could have an inhibitory effect on the formation and/or proliferation of erythroid 
progenitors in vivo (Larsson et al., 2001). Our results indicate that TGFβ1 inhibits 
EryP progenitor formation during ES cell differentiation. Importantly, TGFβ1-
treated EBs also show increased Runx1 expression. Tgfβ1-/- and Alk5-/- EB cells 
display larger EryP populations and decreased Runx1 expression, relative to 
wild-type. These results suggest that TGFβ1 signaling negatively regulates EryP 
development, possibly through upregulation of Runx1. In agreement with this, 
overexpression of Runx1 suppresses increased EryP production caused by 
inhibition of the interaction between TGFβ and ALK5.  Based on these 
observations, generating inducible RUNX1 in Alk5-/- ES cells would be a way to 
examine the negative role of the ALK5-RUNX1 axis in EryP development.  
Examining ectopic expression of Runx1 in Alk5+ cells by generating Alk5-cre; 
Rosa26 loxP-stop-loxP Runx1 mice would also provide important information. 
 It is worthwhile to note that when TGFβ1 was added to both wild-type, 
Runx1+/- and Runx1-/- EB cells, followed by EryP replating, a comparable 
reduction of EryP colonies was observed in both groups. It is likely, therefore, that 
TGFβ1 inhibits EryP development through other mechanisms, in addition to the 
Runx1-dependent pathway. This likelihood is supported by other recent studies. 
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TGFβ1 has, for instance, been shown to induce an epithelial-to-mesenchymal 
transition (EMT) by directly upregulating Snail1 in cultured hepatocytes (Kaimori 
et al., 2007) or by indirectly upregulating Zeb1 through a mechanism mediated by 
Ets1 in epithelial cells (Shirakihara et al., 2007). Comparing the gene-expression 
profiles of wild-type and Runx1-/- EBs after treatment with TGFβ1 would provide 
additional insight into the roles of other possible mediators of TGFβ signaling in 
the suppression of EryP progenitor development, independent of Runx1. 
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Chapter 2.1 
Introduction 
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Hematopoietic Stem Cell Niche 
 Hematopoietic stem cells (HSCs) are responsible for production of all 
blood cells. The bone marrow is the major site of hematopoiesis throughout adult 
life. HSCs reside mainly in the bone marrow and undergo well-controlled cell 
division to regenerate themselves while also producing progenitor cells that give 
rise to all types of mature blood cells. The maintenance of the identity and 
function of HSCs in vivo is thought to depend on a specific microenvironment of 
surrounding cells in the bone marrow known as the HSC niche (Wilson and 
Trumpp, 2006). The HSC niche microenvironment is thought to supply necessary 
factors that support specific aspects of hematopoiesis, such as HSC survival, 
self-renewal, and differentiation. The identification of the cellular components and 
mechanisms that comprise the HSC niche is an area of active investigation. 
 The endosteum is a thin layer of connective tissue that is located at the 
interface between bone and bone marrow. The endosteum surface, covered by 
bone-lining cells, contains a population of cells that can differentiate into bone-
forming osteoblasts. A number of studies have shown that HSCs are commonly 
found at or near the endosteum in the bone marrow, in close proximity to 
osteoblasts, suggesting osteoblasts may serve as part of the HSC niche (Arai et 
al., 2004; Kiel et al., 2005; Nilsson et al., 2001; Suzuki et al., 2006; Zhang et al., 
2003).  Additionally, in vitro studies have demonstrated that human osteoblasts 
have the ability to produce important hematopoietic cytokines, such as 
granulocyte colony-stimulating factor (G-CSF) and hepatocyte growth factor 
(HGF), that support the proliferation of human hematopoietic progenitor cells 
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(CD34+ bone marrow cells) that were enriched in HSCs (Taichman et al., 2001; 
Taichman and Emerson, 1994; Taichman et al., 1996).  
Parathyroid hormone (PTH) is a major regulator of calcium homeostasis, 
playing an important role in both the formation and resorption of bone. In a study 
by Calvi et al., transgenic mice (col1-caPPR) were generated which expressed 
constitutively activated PTH or the PTH-related protein (PTHrP) receptor (PPR) 
under control of the type-1 collagen α1 (Col1α1) promoter, which is active in 
osteoblastic cells (Calvi et al., 2003; Calvi et al., 2001). These transgenic mice 
displayed significant increases in the numbers of osteoblasts and functional 
HSCs in the bone marrow. PTH administered directly to wild-type animals also 
expanded the populations of both osteoblasts and HSCs (Calvi et al., 2003). In a 
separate study, mice engineered with a conditional inactivation of bone 
morphogenic protein receptor 1A (Bmpr1a), which is normally expressed in 
osteoblast cells but not in HSCs, showed a positive correlation between the 
number of osteoblasts and functional HSCs (Zhang et al., 2003). In the same 
study, it was also reported that HSCs were found in close contact with spindle-
shaped, N-cadherin-positive osteoblasts on the endosteal surface (Zhang et al., 
2003). Conversely, by using a transgenic mouse which allowed for the 
conditional destruction of osteoblasts, Visnjic et al. demonstrated that ablation of 
osteoblasts led to a decrease in the absolute number of HSCs in the bone 
marrow and a transfer of a substantial proportion of hematopoietic activity to the 
spleen and liver (Visnjic et al., 2004). These studies show that the number of 
osteoblasts in the bone marrow microenvironment is directly related to the 
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number of functional HSCs or hematopoietic progenitors, indicating that 
osteoblasts, or a subset of osteoblast cells, serve as important components of 
the HSC niche cells. 
 Bone homeostasis is tightly regulated not only by osteoblasts, but also by 
osteoclasts, which are specialized bone resorbing cells of hematopoietic origin. 
Osteoclasts have also been suggested to be components of the HSC 
microenvironment. Specifically, activation of osteoclasts promotes the 
mobilization of hematopoietic progenitors into circulation, suggesting that 
osteoclast activity may play a part in the regulation of the endosteal HSC niche 
(Kollet et al., 2006). Many studies have also proposed that osteoblasts and 
osteoclasts express a variety of factors, including osteopontin, angiopoietin-1, 
matrix metalloproteinase 9 (MMP9), and cathepsin K, which regulate the 
maintenance and localization of HSCs in the bone marrow (Arai et al., 2004; 
Kollet et al., 2006; Nilsson et al., 2005; Stier et al., 2005). In addition to the 
critical role of osteoblasts in supporting the maintenance of HSCs, osteoblasts 
have also been shown to influence B-lymphocyte commitment and differentiation 
(Visnjic et al., 2004; Wu et al., 2008; Zhu et al., 2007). Collectively, these studies 
suggest that there is a close relationship between bone homeostasis and 
hematopoiesis. 
 Other cellular components in the bone marrow have also been suggested 
to function in HSCs maintenance during adulthood. In vivo and tissue section 
images have shown HSCs are also located in close proximity to endothelial cells 
in the bone marrow, indicating that endothelial cells may also serve as important 
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components in the HSC niche (Kiel et al., 2005; Sipkins et al., 2005). In vitro 
experiments showed that vascular endothelial cells that were isolated either from 
embryonic tissues or from some adult non-hematopoietic tissues maintain the 
repopulating capacity of HSCs or support the expansion of hematopoietic 
progenitors (Li et al., 2003; Li et al., 2004; Ohneda et al., 1998). These studies 
suggest that endothelial cells express factors that promote the maintenance of 
HSCs in vitro. Moreover, perivascular reticular cells with high expression of 
CXCL12, a cytokine required for the maintenance of HSCs, have also been 
found in close contact with HSCs in the bone marrow suggesting a possible role 
of reticular cells in supporting HSCs (Sugiyama et al., 2006). Recently, Naveiras 
et al. demonstrated that bone-marrow adipocytes act as negative regulators in 
HSC maintenance (Naveiras et al., 2009). Together, these studies demonstrated 
that, in addition to the important role of bone homeostasis in HSC maintenance, 
the HSC niche in bone marrow could be influenced by multiple cell types found 
either at or near the endosteum, each of which may have different functions in 
the regulation or maintenance of HSCs. 
 However, the correlation between bone homeostasis and HSC 
maintenance were found in physiological states; whether the relationship 
between these two systems in pathological conditions would be disturbed 
remains uncertain. 
 
The K/BxN Mouse Model of Inflammatory Arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory disease which affects 
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approximately 1% of the world’s population (Weinblatt and Kuritzky, 2007). A 
hallmark of this disease is the progressive destruction of peri-articular bone 
(bone near the joints) which leads to bone erosion and functional disability. In 
addition to join destruction, human RA patients also display systemic 
osteoporosis (Haugeberg et al., 2000; Spector et al., 1993). The etiology and 
pathogenesis of RA remain poorly understood. In RA research, animal models 
have been used as important tools for studying pathways and mechanisms 
involved in inflammatory arthritis. One of the most-studied models is the 
KRNxNOD (herein K/BxN) mouse model. K/BxN mice develop an inflammatory 
joint disease that is very similar to human rheumatoid and inflammatory arthritis 
(reviewed in Mandik-Nayak and Allen, 2005). 
 This model was developed as follows: the KRN-C57BL/6 (herein KRN) 
transgenic mouse was originally designed to study the specificity of T-cell 
receptors (TCRs) recognizing an epitope of bovine RNase (Kouskoff et al., 1996; 
Kouskoff et al., 1995). KRN transgenic mice display a normal phenotype under 
the C57BL/6 background. Intriguingly, when those KRN mice are crossed with 
non-obese, diabetic (NOD) mice, all of the F1 progeny (K/BxN) spontaneously 
exhibit a rapid, symmetrical onset of joint inflammation, primarily restricted to the 
joints of the front and rear limbs at around 30±5 days of age (Kouskoff et al., 
1996). Many characteristics of the inflammation in K/BxN mice are similar to 
human rheumatoid arthritis, including pannus formation, synovial hyperplasia, 
increased synovial volume, massive leukocyte infiltration, cartilage destruction, 
and bone erosion, followed by remodeling in the distal joints in the later stages 
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(Kouskoff et al., 1996). When KRN mice and C57BL/6 mice that were congenic 
for the NOD MHC H-2g7 (C57BL/6.H-2g7; herein G7) were crossed, the offspring 
(KRNxG7) all developed inflammatory symptoms which were indistinguishable 
from those seen in K/BxN mice, indicating that MHC class II molecule I-Ag7 was 
responsible for promoting arthritis in K/BxN mice (Kouskoff et al., 1996). 
 Subsequent studies found that the autoimmune response that is 
responsible for the inflammation seen in K/BxN mice is initiated by TCR 
recognition of a ubiquitously-expressed self-peptide derived from the glycolytic 
enzyme glucose-6-phosphate isomerase (GPI) presented by the I-Ag7  MHC 
molecule on B-cells, resulting in production of high titers of autoantibodies 
against GPI (Matsumoto et al., 1999). Arthritic symptoms can be transferred to 
wild-type recipients by injecting them with serum from K/BxN or KRNxG7 mice, 
which contains a high level of GPI autoantibodies (serum-transfer model), but the 
serum-induced disease resolves within a few weeks (Korganow et al., 1999; 
Maccioni et al., 2002; Matsumoto et al., 1999). Thus, the serum-transfer model 
serves as an acute inflammation model, whereas the K/BxN transgenic mice 
serve as a chronic inflammatory model. 
 Many studies have demonstrated that joint destruction in rheumatoid 
arthritis in humans is linked to the activation of osteoclasts in the joints 
(Gravallese et al., 1998; Gravallese et al., 2000; Shigeyama et al., 2000). 
Receptor activator of nuclear factor-κB ligand (RANKL) is a cytokine that  
regulates the completion of the final steps of osteoclast differentiation, as well as 
for their bone resorbing activity (Kong et al., 1999; Lacey et al., 1998). Several 
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pro-inflammatory cytokines, such as interleukin (IL)-1, IL-6, IL-17 and especially 
tumor necrosis factor (TNF)-α, can induce and enhance RANKL expression 
(Kotake et al., 1999; Lam et al., 2000; Wei et al., 2005; Wong et al., 2006). It has 
been demonstrated that RA patients produce excessive TNF-α and RANKL (Chu 
et al., 1991; Gravallese et al., 2000; Takayanagi et al., 2000). K/BxN mice also 
display high levels of TNF-α and IL-6 in their joints (Kouskoff et al., 1996). Mice 
with defective osteoclasts or limited osteoclastogenesis are resistant to both 
K/BxN serum-induced and TNF-α-mediated joint destruction (Pettit et al., 2001; 
Redlich et al., 2002). 
 Most studies using K/BxN mouse model have focused on identifying 
cellular components and pathogenic mechanisms involved in the initiation of 
joint-specific inflammation and destruction of joints (Akilesh et al., 2004; Corr and 
Crain, 2002; Ji et al., 2002a; Ji et al., 2002b; Lee et al., 2002; Pettit et al., 2001; 
Watts et al., 2005; Wipke and Allen, 2001), whereas associated conditions, such 
as systemic osteoporosis, have not been carefully characterized in the mouse 
model.  
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Overall Goals of Chapter Two 
 Hematopoietic stem cells (HSCs) reside mainly in the bone marrow and 
undergo well-controlled cell division to regenerate themselves while also 
producing progenitor cells that differentiate to all types of mature blood cells 
throughout adult life. The maintenance of HSCs in the bone marrow has been 
suggested to have a close association with bone homeostasis in normal 
physiological states, but little is known about their relationship in pathological 
conditions. The objective of chapter two is to investigate the relationship between 
hematopoiesis and bone homeostasis in pathological conditions using a mouse 
model of chronic inflammatory arthritis. 
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Abstract 
Recent studies support the notion that there is an intricate relationship between 
hematopoiesis and bone homeostasis in normal steady states. By utilizing mice 
undergoing chronic inflammatory arthritis, we investigated the relationship 
between hematopoiesis and bone homeostasis in pathologic conditions. We 
demonstrate that mice undergoing chronic inflammatory arthritis displayed 
osteoporosis due to a severe defect in osteoblast function. Despite the defective 
osteoblast function, however, the hematopoietic stem cells from these mice 
exhibited normal properties in either long-term repopulation or cell cycling. 
Therefore, the bone forming capacity of osteoblasts is distinct from their ability to 
maintain hematopoietic stem cells in chronic inflammatory conditions.  
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Introduction 
Under normal physiologic conditions, hematopoietic stem cells (HSCs) residing 
within the specialized bone marrow (BM) niche maintain a balance between self-
renewal and differentiation and provide continuous supply of circulating mature 
immune cells with a limited life span. An intricate relationship exits between 
hematopoiesis and bone homeostasis. As such, osteoblasts serve as a HSC 
niche, while osteoclasts mediate HSC and progenitor egress from the BM (Kollet 
et al., 2007; Purton and Scadden, 2006). Specifically, an increase in osteoblast 
number and/or activation through conditional Alk3 deletion or parathyroid 
hormone administration augments the HSC frequency in BM (Calvi et al., 2003; 
Zhang et al., 2003). Conversely, ablation of osteoblasts results in a decrease in 
absolute number of phenotypic primitive hematopoietic progenitors (Visnjic et al., 
2004). 
 
Rheumatoid arthritis (RA) is a chronic systemic inflammatory autoimmune 
disease of unknown etiology afflicting 1% of the population.  It leads to 
destruction of cartilage and bone at multiple joints with a distal to proximal 
preference. RA is also attended by systemic osteoporosis. However, the 
mechanisms of RA-associated osteoporosis are less appreciated than how joints 
are destroyed. The KRNxNOD (herein K/BxN) mouse model of inflammatory 
arthritis recapitulates many of the features of human RA (Kyburz and Corr, 2003; 
Monach et al., 2007). These mice were generated fortuitously when mice 
transgenic for a T cell receptor recognizing an epitope of bovine RNase 
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(C57BL/6.KRN, herein KRN) were bred onto a NOD background (Kouskoff et al., 
1996). They developed spontaneous chronic and severely destructive arthritis 
with 100% penetrance that resembled human RA (Kouskoff et al., 1996). KRN 
with a C57BL/6 line congenic for the NOD MHC H-2g7 (C57BL/6.H-2g7; herein G7) 
was used to distinguish the contribution of MHC from non-MHC NOD-derived 
genes to disease development. The KRNxC57BL/6.H-2g7 (herein KRNxG7) 
offspring all develop overt joint swelling and the histological hallmarks of arthritis 
of K/BxN mice, indicating that H-2g7 is sufficient for RA development (Kouskoff et 
al., 1996). 
 
By utilizing a KRNxG7 mouse model, we investigated the relationship between 
HSCs and bone homeostasis in chronic inflammatory conditions. We 
demonstrate that similar to patients with RA, mice with inflammatory arthritis 
develop osteoporosis. However, unlike the osteolyisis of inflamed joints, which 
reflects accelerated osteoclast activity, the systemic bone loss of arthritic mice is 
the result of arrested osteoblast function. This conclusion is consistent with the 
decrease in generation of mature osteoclasts in vivo. Unexpectedly, the 
osteoblast deficiency in bone formation did not affect the long term repopulating 
potential of HSCs in these arthritic mice. Collectively, we provide evidence that 
marrow HSCs can be maintained in the absence of functional osteoblasts in 
chronic inflammatory environments. 
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Materials and Methods 
Mice  
KRN (TCR transgenic) mice on a C57BL/6 background were crossed with G7 (I-
Ag7) to generate KRNxG7 mice. C57BL/6J (CD45.2 allele) and B6.SJL-
PtprcaPep3b/BoyJ (CD45.1 allele) mice were obtained from The Jackson 
Laboratory (Bar Harbor, ME).  All animals were housed in accordance with 
National Institutes of Health and American Association for Accreditation of 
Laboratory Animal Care regulations, and animal protocols were reviewed and 
approved by the Washington University animal studies committee. 
 
Cell preparation and Flow Cytometric Analyses (FACS) 
Bone marrow cells were prepared by vigorously flushing femur and tibia 6-8 
times. Peripheral blood was obtained by retro-orbital collection. Spleen cells were 
prepared by gently crushing the tissue and filtering through a 40μm cell strainer 
(BD Falcon). Liver cells were obtained by gently crushing the tissue and filtering 
through a 70μm cell strainer (BD Falcon). All collected cells were treated with 
RBC lysis buffer (Roche) before analyses.  
 
FACS analyses were performed as described previously (Park et al., 2004). For 
KSL analysis we used FITC-conjugated antibodies against CD4, CD8, Mac-1, 
Gr-1, Ter119, and B220 (lineage marker antibodies, BD Biosciences or 
eBioscience), PE-conjugated anti-Sca-1, PerCP/Cy5.5-conjugated anti-CD45, 
and APC-conjugated anti-c-Kit (eBioscience). For some experiments anti-CD45 
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APC-Alexa 750 (eBioscience) or anti-c-Kit PerCP/Cy5.5 (Biolegend) were used. 
SLAM analysis was performed using anti-CD150 PE (Biolegend), anti-CD48 
FITC (eBioscience) and anti-CD41 FITC (BD Biosciences). Mature lineage 
analysis was performed with FITC and PE conjugated antibodies to the lineage 
markers mentioned above as well as Alexa 647 conjugated anti-Mac-1 (BD 
Biosciences) and APC conjugated F4/80 (eBioscience).  
 
LMPP (Lymphoid Primed Multipotential Progenitor; Kit+Sca1+Lin-Flk2hiCD34+) 
and CLP (Common Lymphoid Progenitor; Lin-Flk2+IL-7Rα+) analyses were 
performed with the following fluorophore conjugated antibodies: α-Sca1-FITC, α-
IL-7Rα-biotin, α-cKit-APC-Alexa 750 (eBioscience), α-Flk2-PE, α-CD34-
Alexa647, α-Lineage-APC cocktail, Streptavidin-PerCP/Cy5.5 (BD Biosciences) 
and α-Lineage-biotin cocktail (Miltenyi). PreproB analysis was performed with α-
IgM-FITC, α-CD43-PE, α-NK1.1 PerCP/Cy5.5, α-CD11c PE-Cy7, α-B220-biotin 
(BD Bioscience), α-CD19-Alexa647, Streptavidin APC-eFluor 708 (eBioscience). 
Other antibodies used for B cell precursor analysis were α-B220-PerCP/Cy5.5 
(eBioscience) and α-AA4.1-FITC (BD Bioscience). Cells were analyzed using a 
Facscalibur (4-color), a FACScan adapted for 5 color analysis, or FACScanto (6 
color) and data analyzed with Cell Quest (BD) or Flow Jo softwares (Tree Star). 
 
BrdU labeling 
KRNxG7 and control mice (6-8 week old) were injected with a single dose (1mg 
per 6g of body mass) of sterile-filtered BrdU (Sigma) dissolved in PBS. Mice 
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were sacrificed 2-3 hours later and bone marrow cells harvested as described 
earlier.  Harvested bone marrow cells were subjected to lineage cell depletion by 
magnetic separation using the lineage cell depletion kit (Miltenyi). Lineage 
depleted cells were stained with α-cKit-FITC (eBioscience), α-Sca1-PE and 
Streptavidin-PerCP-Cy5.5 (BD Pharmingen).  Cells were subsequently fixed and 
intracellularly stained with APC conjugated α-BrdU antibody using the APC-BrdU 
flow kit (BD Pharmingen).  Cells were analyzed using the BD FACScalibur and 
data analyzed using BD Cell Quest software. 
 
Ki67/Hoechst Analysis 
Lin+ cells were depleted from bone marrow by magnetic sorting as described 
above using biotin-conjugated anti-Lin antibodies (Miltenyi). Cells were surface 
stained with α-Sca1 PE, Streptavidin PerCP/Cy5.5 (BD Bioscience) and α-cKit 
APC (eBioscience). Ki67/Hoechst staining has previously been used to assess 
KSL cycling and our method was adapted from this previous study (Wilson et al., 
2004). Surface stained cells were fixed and permeabilized using BD 
Cytofix/Cytoperm buffer followed by intracellular staining with α-Ki67 FITC for 30 
minutes followed by a 5 minute Hoechst incubation (20μg/ml). 5-color flow 
cytometry was performed with a MoFlo (Dako), which has UV excitation 
capability. Data analysis was performed with Summit or FlowJo softwares. 
Doublets were excluded in the gated populations that were analyzed for Ki67 
expression. The Ki67 negative population was defined based on staining a 
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control population of cells with a FITC conjugated isotype control antibody (BD 
Biosciences). 
 
Progenitor assay 
Cells from bone marrow and spleen were replated in Methocult M3434 (Stemcell 
Tech, CA).  Colonies were counted 7-10 days later.  
 
Cell transplantation 
For serial bone marrow transplantation, lethally irradiated (1,000Rads) B6xG7 
(CD45.1xCD45.2) recipients were injected (i.v.) with unfractionated 1x106 BM 
cells from 6 week old KRNxG7 (CD45.2xCD45.2) or B6xG7 (CD45.2xCD45.2) 
mice (five recipients for each group). PB samples were analyzed for CD45.1 and 
CD45.2 every 4 weeks. Seven months after transplantation, bone marrow 
suspensions were prepared from primary recipients and 1x106 nucleated cells 
were injected into new lethally irradiated B6xG7 (CD45.1xCD45.2) recipient mice 
(8 for control and 9 for KRNxG7). The tertiary transplantation was performed 
seven months after secondary transplantation (7 for control and 9 for KRNxG7). 
The recipients of serial bone marrow transplantation were subjected to lineage 
analyses for donor contributions 6 or 7 months after transplantations. 
 
Competitive repopulation assay has been described previously (Stier et al., 2005).  
Briefly, 6-week old B6xG7 (CD45.2xCD45.2) or KRNxG7 (CD45.2xCD45.2) bone 
marrow cells, 2x105, were mixed with 2x105 B6xG7 (CD45.1xCD45.2) competitor 
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bone marrow cells and injected (i.v.) into lethally irradiated (1000 Rads) B6xG7 
(CD45.1xCD45.2) recipient mice. Peripheral blood (PB) samples were collected 
retro-orbitally three and five months after transplantation and analyzed for 
CD45.1 and CD45.2. 
 
Lineage negative (Lin-) spleen cells from 6-week old B6xG7 (CD45.2xCD45.2) or 
KRNxG7 (CD45.2xCD45.2) mice were isolated using MACS Lineage Cell 
Depletion Kit (Miltenyi Biotec). Onex105 sorted Lin- cells were injected into 
lethally irradiated (1,000Rads) B6xG7 (CD45.1xCD45.2) recipients. 
Reconstitution of donor-derived cells (CD45.2) was monitored by staining retro-
orbitally obtained peripheral blood cells with monoclonal antibodies against 
CD45.2 and CD45.1 (eBioscience) followed by FACS analysis.  
 
Serum TRAP5b activity and serum osteocalcin activity 
Blood was collected retro-orbitally under anesthesia prior to sacrifice.  The serum 
TRACP5b activities of 6 week old G7 and KRNxG7 mice were measured by 
MouseTRAPTM Assay ELISA kit (Immunodiagnostic Systems Inc.).  Serum 
Osteocalcin levels of 6 week old G7 and KRNxG7 mice were measured by 
Mouse Osteocalcin ELISA kit (Biomedical Technologies Inc.). 
 
Histology and Histomorphometry 
The tibiae of 6-week old B6xG7 and KRNxG7 mice were fixed with 70% ethanol 
followed by plastic embedding and Goldner staining, or with 10% neutral buffered 
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formalin followed by the decalcification in 14% EDTA for 4-5 days, paraffin 
embedding, and TRAP staining. Calcein (Sigma) (7.5 mg/kg, i.p) was injected on 
day 7 and 12. Mice were sacrificed on day 14. Osteoclastic and osteoblastic 
perimeters were measured and analyzed using Osteomeasure (OsteoMetrics, 
Atlanta, GA) in a blinded fashion. 
 
μCT 
The trabecular volume in the distal femoral metaphysic was measured using a 
Scanco μCT40 scanner (Scanco Medical AG, Basserdorf, Switzerland).  A 
threshold of 300 was used for evaluation of all scans. 30 slices were analyzed, 
starting with the first slice in which condyles and primary spongiosa were no 
longer visible. 
 
qRT-PCR 
RNA preparation and cDNA synthesis were previously described (Lee et al., 
2008). Primer sequences used in this study are provided in supplementary Table 
2.2-1.  
 
Statistical Analyses  
Statistical significance was assessed by two-tailed Student’s t test.  Values of 
P<0.05 were considered statistically significant. 
 
Total bone marrow cell isolation 
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Bone marrow isolation by crushing and enzymatic digestion was performed as 
done previously (Haylock et al., 2007) using the Hematopoietic Stem Cell 
Isolation Kit (Millipore). Briefly, one femur and one tibia were collected and 
ground in a mortar and pestle in PBS with 4% FCS. The cells and small bone 
fragments were washed with PBS with 4% FCS and filtered through a 40 μm cell 
strainer. Small bone fragments were incubated with 3 mg/ml Collagenase Ι and 4 
mg/ml Dispase ΙΙ (Stem Cell Isolation Kit, Millipore) for 5 minutes at 37oC in an 
orbital shaker. The fragments were washed and cells were collected by filtered 
through 40 μm cell strainer. Bone marrow from the contralateral femur and tibia 
were obtained by vigorous flushing as described in Methods. Cells retrieved by 
both isolation methods were RBC lysed, count on a hemocytometer and FACS 
analysed for KSL frequency. 
 
Alkaline Phosphatase (AP) expression assay 
The details of AP expression assay on bone marrow stromal cells (BMSCs) are 
previously described (Tu et al., 2007). Briefly, Cells were harvested 3 days later 
after 100% confluence and tested by a biochemical assay using p-nitrophenyl 
phosphate (Sigma, St. Louis, MO) as a substrate; for mineralization assays, cells 
were switched to mineralization medium containing 50 ug/ml ascorbic acid + 50 
mM β-glycerophosphate for 2 weeks and changed medium every 3 days. The 
nodule formation was verified by von Kossa staining. 
 
Osteoblast differentiation assays 
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Mineralization assays on BMSCs were performed as previously described (Tu et 
al., 2007) with a slight modification. Basically, femurs and tibia were aseptically 
removed from 6-weeks-old G7 and KRNxG7 mice. After the ephiphyseal ends of 
each bone were cut off, bone marrow was flushed out with 1 ml of alpha-MEM 
using a 25-gauge needle. Cells were treated with 1 ml of red blood cell lysis 
buffer (Roche, Indianapolis, IN) for 5 min at room temperature, rinsed and 
resuspended in alpha-MEM containing 20% fetal bovine serum. After filtered 
through a 70 µm cell strainer, the cells were seeded at 2x106/well in 12-well 
plates. Half of medium was changed at day 3 and all medium at day 6. 
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Results  
KRNxG7 mice are osteoporotic due to diminished bone formation  
K/BxN and KRNxG7 mice develop arthritic symptoms including ankle swelling 
shortly after 3 weeks of age (Kouskoff et al., 1996). The ankle thickness 
increases up to 5-6 weeks of age reaching a maximum of 4-5mm and remaining 
constant at a slightly lower level thereafter (Kouskoff et al., 1996). Typically, 6 
week-old KRNxG7 mice in C57BL/6 genetic background were used in this study, 
as they show overt inflammation at this time point. As expected, KRNxG7 mice 
develop rheumatoid joint pannus and lysis of peri-articular bone (Figure 2.2-1A, 
B). Since human inflammatory arthritis is also attended by systemic bone loss, 
we asked if the same holds true in this murine model. Radiographs of KRNxG7 
tibiae showed destruction of epiphyseal bone as well as metaphyseal 
demineralization. Histomorphometric and µCT analysis of the same bones 
established a marked reduction of trabecular bone volume and consequently 
increased trabecular spacing (Figure 2.2-1C,D, F). A DEXA analysis exhibited 
decreased bone mineral density in arthritic mice (Figure 2.2-1E). Despite the 
profound metaphyseal osteoporosis, however, the number of mature resorptive 
cells was decreased in the marrow of endosteal bone (Figure 2.2-1G). This 
observation was confirmed by diminished serum levels of the global osteoclast 
marker TRAP5b (Figure 2.2-1H) and impaired expression of osteoclast specific 
genes in whole bone marrow (Figure 2.2-1I).  
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The chemokine SDF-1 plays a critical role in osteoclastogenesis by promoting 
osteoclast differentiation and the cell’s longevity (Wright et al., 2005; Zannettino 
et al., 2005). In addition, inhibition of BM SDF-1 expression promotes osteoclast 
progenitor cell mobilization to the periphery (Zhang et al., 2008). We found that 
SDF-1 BM mRNA levels were decreased in KRNxG7 mice and thus its 
suppression likely mediates, at least in part, the noted in vivo arrest of terminal 
osteoclast differentiation (Figure 2.2-1J). Because TNF-α, which accelerates 
osteoclast progenitor mobilization in inflammatory erosive arthritis, also 
suppresses SDF-1 expression (Zhang et al., 2008), we posited that TNF-α level 
is increased in KRNxG7 mice. We indeed found that TNF-α mRNA and protein 
are increased in KRNxG7 BM and serum, respectively (Figure 2.2-1J & data not 
shown). Thus, although a direct link between TNF-α and SDF-1 in KRNxG7 mice 
needs to be established, in face of suppressed Sdf-1 expression, osteoclast 
progenitor cells most likely do not readily assume the full resorptive phenotype 
but are mobilized to the periphery and migrate to the inflamed joint, which they 
degrade upon maturation. 
 
Osteoporosis may reflect stimulated osteoclast or diminished osteoblast activity. 
KRNxG7 mice have reduced marrow osteoclasts in face of systemic 
osteoporosis suggesting that the paucity of bone extant in these animals reflects 
suppressed bone formation. To address this issue, we first histomorphometrically 
determined the number of trabecular osteoblasts/mm bone surface, which we 
found indistinguishable in KRNxG7 and G7 mice (Figure 2.2-2A). Moreover, in 
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vitro osteoblast formation and bone nodule formation assessed by alkaline 
phosphatase activity and mineralization assays, respectively, were 
indistinguishable between KRNxG7 and controls (Supplementary Figure 2.2-1a, 
b). However, the percentage of metapyhseal bone surface covered by osteoid 
was reduced in the arthritic mice suggesting that the bone synthesizing 
population was diminished (Figure 2.2-2B). This posture was confirmed by 
dynamic histomorphometry, which established that the rate of metaphyseal bone 
formation is less than 1/3 of control (Figure 2.2-2C). Similarly, serum Osteocalcin 
as well as Osteocalcin mRNA, a marker of global bone formation, was reduced in 
KRNxG7 mice (Figure 2.2-2D, E). Additionally, mRNA expression of osteoblast 
specific genes, receptor activator of NFkappaB ligand (Rankl), Osteoprotegerin 
and Runx2 was all markedly diminished (Figure 2.2-2E). Thus, the systemic 
osteoporosis attending the inflammatory arthritis of KRNxG7 mice reflects 
diminished bone formation and not accelerated bone resorption. 
 
Systemic increase in Gr1+ cells and decrease in B220+ cells accompanied 
by impaired KRNxG7 marrow B lymphopoiesis  
Our data so far shows that osteoblasts are functionally defective in KRNxG7 
mice. In addition to bone formation, osteoblasts have been reported to play 
crucial roles in hematopoiesis by providing a niche to maintain HSCs and 
supporting B lymphopoiesis (Arai et al., 2004; Calvi et al., 2003; Visnjic et al., 
2004; Wu et al., 2008; Zhang et al., 2003; Zhu et al., 2007). We noticed that 
KRNxG7 bone marrow cellularity was higher (~50% more) compared to that of 
 131 
controls irrespective of the method of bone marrow collection (Supplementary 
Figure 2.2-2a). To investigate the specific hematopoietic changes occurring in 
chronic inflammation, we examined mature hematopoietic cell lineages in BM, 
spleen, liver and peripheral blood (Figure 2.2-3A). There was an increase in 
myeloid cells, specifically Gr1+, cells in all KRNxG7 tissues analyzed. Myeloid 
cells including neutrophils are abundant in the joint inflammation of human RA 
patients (Haynes, 2007) and are critical for the disease, as depletion of 
neutrophils or macrophages ameliorates inflammatory joint disease in a serum 
transfer model of RA (Solomon et al., 2005; Wipke and Allen, 2001). In KRNxG7 
mice, T cells (detected by CD3, CD4 or CD8) bearing T cell receptor (TCR) 
transgene undergo negative selection (Kouskoff et al., 1996). Thus, as expected, 
T cells were reduced.  
 
A decrease was also seen in B220+ cells in KRNxG7 mice for all tissues 
analyzed (Figure 2.2-3A) and this indeed reflects a decrease in B lineage cells 
not merely a decrease in B220 expression (Supplementary Figure 2.2-3a). To 
determine if defective marrow B lymphopoiesis in KRNxG7 mice could at least in 
part explain the diminution in B220+ frequency we examined the frequency of 
marrow B cell precursors. We found that a majority of the residual B220+ cells in 
KRNxG7 marrow were B cells (B220hiIgM+) cells with almost complete depletion 
of B cell precursors (B220loAA4.1+)(Figure 2.2-3B & data not shown)(Hardy et al., 
1991; Li et al., 1996). Further analysis revealed that not only were B cell 
committed, pre-proB, proB and preB, precursors absent but common lymphoid 
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progenitors (Karsunky et al., 2008) were also absent from KRNxG7 marrow 
(Figure 2.2-3C & Supplementary Figure 2.2-3b). Analysis of whole bone marrow 
gene expression also revealed a downregulation in several marrow B 
lymphopoiesis promoting factors including SDF-1, IL-7 and Flt3-L (Figure 2.2-1J 
& 2.2-3D). Therefore, KRNxG7 mice have impaired marrow B lymphopoiesis 
attending the defective osteoblasts.  
 
The frequency of c-Kit+Sca1+Lin- cells is not changed in KRNxG7 bone 
marrow  
Based on the current understanding that endosteal osteoblasts serve as a HSC 
niche and maintain the quiescence of the HSCs (Arai et al., 2004; Calvi et al., 
2003; Zhang et al., 2003), the impairment of osteoblast bone forming capacity in 
KRNxG7 mice raised the possibility that its role in the HSC niche was also 
compromised. To determine if HSC and progenitor cell homeostasis was affected 
in the absence of functional osteoblasts in chronic inflammatory arthritic 
environments, we subjected KRNxG7 and control BM, spleen, liver and 
peripheral blood cells to CD45 (pan hematopoietic marker), c-Kit, Sca-1 and 
Lineage (Lin) marker staining. The frequency of HSC enriched KSL cells in the 
bone marrow was similar between the control and KRNxG7 mice when examined 
at 3 weeks of age, just prior to the onset of joint swelling (Figure 2.2-4A). There 
was no increase in BM cellularity at this age (not shown). The KSL frequency 
was also similar at 6 weeks of age, when all KRNxG7 mice show overt arthritis, 
irrespective of the method of marrow isolation (Figure 2.2-4A & Supplementary 
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Figure 2.2-2b). The frequency of CD150+CD48-CD41- (SLAM) cells, also 
enriched for HSCs (Kiel et al., 2005), in the bone marrow was also similar (Figure 
2.2-4A). As the total bone marrow cellularity was increased (Supplementary 
Figure 2.2-2a), there was a net increase in absolute KSL number in KRNxG7 
bone marrow despite osteoblast deficiency (Supplementary Figure 2.2-2c). 
 
c-Kit+Sca1+Lin- cells in KRNxG7 bone marrow cycle normally  
It has been suggested that quiescence and restricted proliferation of HSCs is 
important in maintaining stem cell properties and that osteoblasts maintain HSCs 
by promoting their quiescence (Arai et al., 2004; Orford and Scadden, 2008; 
Wilson and Trumpp, 2006). We therefore next investigated if KRNxG7 HSCs 
displayed altered proliferation and/or cell cycling. To this end, KRNxG7 arthritic 
as well as B6 control mice were subjected to 5-bromodeoxyuridine (BrdU) 
incorporation and cell cycle analyses. Specifically, mice were injected with a 
single dose of BrdU, sacrificed 2-3 hours later and BM cells were harvested and 
subjected to BrdU staining. There was no difference in BrdU labeling in KSL cell 
populations between control and KRNxG7 BM at 6-8wks, nor at earlier or later 
time points (Figure 2.2-4B & Supplementary Figure 2.2-4). We were also unable 
to detect a decrease in quiescence of KSL cells assessed by Ki67 and Hoechst 
staining (Ki67negHoechstlow, Figure 2.2-4C & Supplementary Figure 2.2-5). For 
unknown reasons, however, more mature progenitor fractions (i.e. Lin-c-
Kit+Sca1- or Lin-) had reduced BrdU positive fraction and increased 
Ki67negHoechstlow suggesting an overall decrease in cycling (Figure 2.2-4B, C). 
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We also compared the expression of several cell cycle regulators including the 
“stemness” gene Bmi in arthritic and control KSL cells but failed to detect any 
differences for most genes (Supplementary Figure 2.2-6). Expression of the cell 
cycle inhibitors, p21 and p27 (Supplementary Figure 2.2-6), was decreased in 
arthritic KSL cells, however, it has previously been shown that complete deletion 
of these genes does not alter HSC function and/or pool size or cycling (Cheng et 
al., 2000; van Os et al., 2007). KRNxG7 KSL cells did not show any significant 
differences in Annexin V staining pattern from controls (not shown), suggesting 
that the KRNxG7 KSL cell survival/longevity is not changed. Collectively, these 
data suggest that KRNxG7 KSL cell cycle is unaltered. 
 
The long term repopulating potential of KRNxG7 hematopoietic stem cells 
is not impaired  
To assess if the properties of HSCs are altered in the defective bone forming 
osteoblast environments, lethally irradiated B6xG7 (CD45.1xCD45.2) recipients 
were transplanted with 1x106 whole BM cells from 6-week old KRNxG7 
(CD45.2xCD45.2) mice. Age matched B6xG7 (CD45.2xCD45.2) BM cells served 
as controls. The donor contribution from KRNxG7 (CD45.2xCD45.2) BM was 
similar to that from B6xG7 (CD45.2xCD45.2) donor cells (Figure 2.2-4D). As 
expected, all blood cell lineages of donor origin were found as evidenced by 
lineage analyses of peripheral blood at 7 months after transplantation, although T 
cell generation was deficient due to negative selection (Supplementary Figure 
2.2-7).  
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 Subsequent secondary and tertiary transplantation studies indicated that 
KRNxG7 HSCs displayed no obvious defects in self-renewal potential 
(Supplementary Figure 2.2-7). To rule out the possibility that the long-term 
repopulation potential of HSCs is diminished in older animals, BM transplantation 
from 4 months old KRNxG7 mice was performed. Again, there was no 
compromise in hematopoietic reconstitution potential of KRNxG7 HSCs from old 
animals (Supplementary Figure 2.2-8). 
 
To further confirm that HSC function was not compromised in these mice, we 
next subjected KRNxG7 HSCs to competitive repopulation studies.(Purton and 
Scadden, 2007) Specifically, B6xG7 (CD45.2xCD45.2) or KRNxG7 
(CD45.2xCD45.2) bone marrow cells were mixed with equal number of B6xG7 
(CD45.1xCD45.2) competitor bone marrow cells (2x105 cells each) and injected 
(i.v.) into lethally irradiated (1000 Rads) B6xG7 (CD45.1xCD45.2) recipient mice. 
Peripheral blood cells were collected and analyzed for CD45.1 and CD45.2. The 
contribution from KRNxG7 bone marrow cells was indistinguishable from that of 
the controls (Figure 2.2-4E). Collectively, we conclude that despite the severe 
defects in osteoblast bone-forming function in KRNxG7 mice, KRNxG7 BM HSC 
cycling was similar to controls and long term repopulating potential of these 
HSCs was not impaired.  
 
c-Kit+Sca1+Lin- cells are maintained in KRNxG7 spleen 
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We noticed that most of the KRNxG7 mice had splenomegaly with no obvious 
hepatomegaly (Supplementary Figure 2.2-9a,b & data not shown). Intriguingly, 
the frequency of KSL cells as well as absolute KSL number was much greater in 
KRNxG7 spleen compared to B6xG7 spleen at 6 weeks of age (Figure 2.2-5A, 
Supplementary Figure 2.2-9c & data not shown). Similar changes in the KSL 
frequency also occurred in K/BxN spleen (data not shown). To confirm that the 
apparently high frequency of phenotypic hematopoietic stem/progenitors in the 
spleen of arthritic mice indeed correlated with an actual increase in functional 
hematopoietic stem/progenitor cells, we performed hematopoietic replating and 
transplantation studies. Specifically, unfractionated bone marrow or spleen cells 
from 6 week old KRNxG7 and KRN controls were cultured in methylcellulose 
hematopoietic replating medium. KRNxG7 splenocytes generated a substantially 
higher number of hematopoietic colonies (Figure 2.2-5B). We further 
transplanted sorted Lin- cells (1x105 cells/mouse) from KRNxG7 
(CD45.2xCD45.2) and control B6xG7 (CD45.2xCD45.2) spleens into lethally 
irradiated B6xG7 (CD45.1xCD45.2) mice. A majority of the mice that received 
Lin- cells from control spleen died within 2 weeks with 100% succumbing within 3 
months. However, a significant number of mice that received Lin- cells from 
KRNxG7 spleen were still survived past 6 months post transplantation (Figure 
2.2-5C, left). A high donor chimerism was obvious when recipients of KRNxG7 
splenic Lin- cells were analyzed 3 months after transplantation (Figure 2.2-5C, 
right). These replating and transplantation studies corroborate FACS analyses 
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showing that functional hematopoietic progenitors are particularly abundant in 
KRNxG7 spleen. 
 
The high frequency of hematopoietic stem and/or progenitor cells in the KRNxG7 
spleen raised a possibility that hematopoietic stem/progenitor cells readily 
mobilized into the periphery in chronic inflammation. However, KSL cells in the 
peripheral blood and other organs such as the liver of KRNxG7 mice were hardly 
detectable and not significantly different from controls (data not shown). 
Moreover, the KSL frequency in B6xG7 and KRNxG7 spleen was similar in 
young mice (1-2 weeks of age). While KSL cells were maintained in KRNxG7 
spleen (6wks), they decreased greatly in age-matched mice (Figure 2.2-5A). We 
suggest that HSCs are sustained in the KRNxG7 spleen, although the possibility 
that hematopoietic stem/progenitor cells are continuously mobilized at very low 
levels to the spleen in chronic inflammatory environments cannot be ruled out at 
this moment.  
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Discussion 
Inflammatory bone loss is associated with several chronic diseases in humans 
including RA (Romas and Gillespie, 2006). Such human inflammatory joint 
disease is generally complicated by systemic osteoporosis, which is particularly 
severe in KRNxG7 mice. While focal destruction of bone, within the rheumatoid 
joint, is the product of aggressive osteoclast recruitment, whether its attendant 
osteoporosis is the product of accelerated resorption or attenuated formation is 
less clear. Given the abundance of systemic inflammatory cytokines, the 
pathogensis of rheumatoid-associated osteoporosis has been assumed to be 
primarily osteoclastic. We demonstrate, however, the number of endosteal 
osteoclasts and confirmatory markers of bone resorption are diminished. 
Although the osteoblast number per bone surface was similar, the absolute 
osteoblast number was reduced in KRNxG7 mice due to decreased trabecular 
bone volume. Given that osteoblast bone forming activity is also ablated, at least 
in the KRNxG7 model of RA, the attendant osteoporosis reflects retarded 
osteogenesis.  
 
Our results extend a growing body of work, examining the relationship between 
bone homeostasis and hematopoiesis, to a disease model. Our findings that 
there was a net increase in absolute number of BM HSCs in osteoblast deficient 
KRNxG7 mice compared with controls seem to be at odds with the current view 
of the role of osteoblasts as HSC niche cells. Specifically, transgenic mice 
expressing a constitutively active PPR (PTH/PTHrP receptors) under the control 
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of the type1(I) collagen promoter (col1-caPPR) stimulated osteoblast and 
increased their number and stromal cells from these mice supported HSCs in 
culture. These transgenic mice as well as parathyroid hormone treatment of wild 
type mice also increased the frequency of KSL cells as well as functional HSCs 
(Calvi et al., 2003). Moreover, poly I:C treatment of Mx1–Cre+Bmpr1a fx/fx mice 
resulted in about two fold increase in the percentage of KSL cells, which 
correlated with an increase in endosteal osteoblast number (Zhang et al., 2003). 
Conversely, ablation of osteoblasts by ganciclovir treatment of transgenic mice 
expressing herpesvirus thymidine kinase (TK) gene under the 2.3kb of the rat 
collagen α1 type I promoter (Col2.3ΔTK) resulted in a decrease in absolute 
number of KSL cells, although the frequency was increased in these mice due to 
reduced BM cellularity (Visnjic et al., 2004). These previous studies will predict 
that HSCs in KRNxG7 bones would be reduced which is contrary to what we 
observe.  
 
We suggest several possible explanations for the apparent discrepancy. First, 
the remaining osteoblasts in the KRNxG7 mice, although reduced in numbers, 
may be sufficient to support the HSC maintenance. Second, osteoblast lineage 
cells are multifunctional. For example they not only manufacture bone, but 
stimulate osteoclastogenesis via expression of RANKL and M-CSF. In fact, there 
are circumstances of disassociation of these events as seen in multiple myeloma 
in which bone formation is arrested but osteoclastogenesis is exuberant, 
presumably reflecting altered Wnt signaling (Oshima et al., 2005). It is therefore 
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possible that KRNxG7 osteoblasts still support the HSC maintenance, although 
their bone forming ability is impaired. In this regard, it is important to note that 
Zhang et al determined histologically that HSCs in BMPR1a conditional knockout 
mice were located adjacent to spindle shaped bone lining cells that express N-
cadherin (Zhang et al., 2003). Bone lining cells are classically regarded as 
quiescent non-functional osteoblasts (Aubin and Turksen, 1996) or immature 
osteoblasts (Zhang et al., 2003) and have distinguished morphology from the 
cuboidal osteoblasts that are responsible for bone formation (Aubin and Turksen, 
1996). Lymperi et al have shown that increasing total osteoblasts without 
increasing N-cadherin+ osteoblasts enhances bone formation without increasing 
HSCs highlighting the dissociation between bone formation and HSC 
maintenance at the cellular level (Lymperi et al., 2008). 
 
Even though HSCs were maintained normally in KRNxG7, B cells were greatly 
reduced in these mice. Previous studies have shown that conditional ablation of 
osteoblasts in Col2.3ΔTK transgenic mice resulted in defects in B lymphopoiesis 
(Visnjic et al., 2004; Zhu et al., 2007). Furthermore, it has been shown that a cell 
autonomous defect of Gsα signaling in osteoblasts also impairs marrow B cell 
development (Wu et al., 2008). Our results are more similar to the effects of 
osteoblast depletion using the Col2.3 TK transgenic system. We find that similar 
to Zhu et al, preproB, proB and pre B precursors are all depleted in KRNxG7 
mice in contrast with Wu et al, where preproB cells are intact. This more severe 
B cell depletion is also reflected by gene expression analysis which reveals a 
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decrease in not just IL-7 as obtained by Wu et al, but also of SDF-1 (which is not 
changed in Wu et al.) and of Flt3-L. Intriguingly CLPs are also absent from 
arthritic bone marrow, suggesting that importance of osteoblasts in marrow B 
lympophopoiesis occurs higher up in the developmental hierarchy than 
previously determined, prior to B cell commitment. It is possible that the 
decreased cycling of Kit+Sca-Lin- cells in KRNxG7 bone marrow is due to 
undefined progenitors in the lymphoid lineage. Previous studies have suggested 
that immunization, infection and inflammatory cytokines can mobilize B cell 
precursors into the periphery (Nagaoka et al., 2000; Ueda et al., 2005; Ueda et 
al., 2004). However it is at the moment unclear if and where B lymphopoiesis 
might be relocated to in the KRNxG7 mice.  
 
Taken together, osteoblast determinants involved in bone formation vs B 
lymphopoiesis vs hematopoietic stem supporting activity could be distinct and 
uncoupled. Alternatively, while osteoblasts maybe obligatory for B cell 
development and bone formation, additional HSC niche cells, such as endothelial 
or reticular cells (Kiel and Morrison, 2006; Sugiyama et al., 2006), could 
compensate for the osteoblast defects in maintaining HSC integrity in 
inflammatory environments of KRNxG7 mice. To this end, previous studies 
demonstrate that endothelial cells of hematopoietic tissues, such as bone 
marrow or extramedullary organs, express cell surface molecules including E-
selectin and VCAM-1. Intriguingly, these molecules are not expressed in 
quiescent endothelium of non-hematopoietic tissues, but become upregulated in 
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inflammation (Mazo et al., 1998; Schweitzer et al., 1996). Thus, it will be 
particularly important to know if the accumulation of HSCs and progenitors that 
we see in the spleens of arthritic mice is associated with changes in the 
endothelial niche in chronic inflammation. Moreover, studies distinguishing the 
requirements of osteoblast vs. endothelial niche in HSC maintenance in normal 
vs. pathologic conditions should be addressed thoroughly in the future.  
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Figure 2.2-1. 
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Figure legends 
Figure 2.2-1. Severe joint destruction and osteoporosis in KRN/G7 mice. 
 (A) Radiographs of femurs of 6 week old G7 and KRNxG7 mice. Right panels 
are higher magnification images of boxed areas in the left panels. Yellow arrow 
and dashed circle in lower right panel denote destroyed articular surface and 
secondary ossification center. Red arrow points to trabecular bone region.  
Green arrow indicates micro-fractures. 
(B) Representative three-dimensional reconstruction of the femur by μCT.   
(C) The percentage of trabecular bone volume/tissue volume determined by μCT 
(BV/TV).  
(D) Trabecular separation determined by μCT (Tb. space).   
(E) DEXA determined bone mineral density (BMD).  Data are presented as mean 
± SD, n=5 in each group of mice.  
(F) ) Histomorphometric determination of BV/TV. Trabecular bone volume 
normalized to total marrow space (BV/TV).  
(G) TRAP (red reaction product) stained histological sections of G7 and KRNxG7 
tibia. Data are expressed as % trabecular bone surface covered by osteoclasts. 
n=5. 
(H) Global osteoclast number, in vivo, was quantified by serum TRAP5b ELISA. 
(I) Oscar, integrinβ3 and cathepsin K expression was analyzed by quantitative 
PCR with RNA from G7 and KRNxG7 BM. Shown is the mean expression ± SD 
for each gene normalized to GAPDH.  n=3. 
 149 
(J) SDF1 and TNF-α expression was analyzed by quantitative RT-PCR with RNA 
from G7 and KRNxG7 BM. Shown is the mean expression ± SD for each gene 
normalized to GAPDH.  n=3. 
*p<0.05, **p<0.01,  ***p<0.001 
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Figure 2.2-2. 
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Figure 2.2-2. Impaired bone formation rate in KRN/G7 mice. 
(A) Osteoblast number/mm bone perimeter (No. OB/B.mm).  
(B) % trabecular surface covered by osteoid (OS.S/B.mm). 
(C) Bone formation rate (BFR) histomorphometrically quantitated from double 
calcein labeled tibia.  
(D) In vivo bone formation was quantified by serum osteocalcin (Osc) level at 6 
weeks of age. n=5. 
(E) RNA of KRN and KRNxG7 BM was analyzed  for gene expression of 
osteoblast markers, receptor activator of NFkappaB ligand (Rankl), 
Osteoprotegerin (Opg), Runx2 and Osteocalcin  by quantitative RT-PCR . Shown 
is the mean expression ± SD for each gene normalized to GAPDH. 
*p<0.05, **p<0.01,  ***p<0.001 
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Figure 2.2-3. 
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Figure 2.2-3. Characterization of mature cells and B cell development 
defect in KRNxG7 mice.  
(A) Systemic increase in myeloid cells and decrease in lymphoid cells. BM, 
spleen, liver and peripheral Blood (PB) cells were harvested from 6 to 8 week old 
KRNxG7 and control (KRN, G7 or B6xG7) mice, stained for the indicated lineage 
markers and analyzed by flow cytometry. B220 is a B cell marker, Gr1 stains 
granulocytes and monocyte populations, Mac1 and F480 combination stains 
macrophages, CD3, CD4 and CD8 stain T cells.   Shown is the mean for 3 to 11 
mice analyzed per strain for each tissue.  
(B) FACS plot for B cell precursors in bone marrow. Bone marrow cells from 
KRNxG7 or G7 controls are stained for B220 and AA4.1 (a marker for B cell 
precursors). B cell precursors (B220loAA4.1+; red arrow) are virtually depleted in 
KRNxG7 bone marrow while most of the residual cells are B220hi and IgM+ (IgM 
staining not shown). 
(C) Systematic analysis of bone marrow B cell development. FACS determined 
frequency of various B cell precursors from earliest (left) to the latest (right) are 
shown. LMPP (Lymphoid Primed Multipotential Progenitor; Kit+Sca1+Lin-
Flk2hiCD34+), CLP (Common Lymphoid Progenitor; Lin-Flk2+IL-7Rα+), PreproB 
(B220+IgM-CD19-CD43+NK1.1-CD11c-), ProB (B220+IgM-CD19+CD43+), PreB 
(B220+IgM-CD19+CD43-), B cells (B220+IgM+). We confirmed that Lin-Flk2+IL-
7Rα+ CLPs were almost predominantly KitloSca1lo (data not shown) as 
previously reported.(Karsunky et al., 2008; Kondo et al., 1997) 
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(D) Expression of various B lymphopoiesis promoting cytokines in whole marrow. 
Expression was determined by quantitative real time PCR, followed by 
normalization to GAPDH. IL-7(Interleukin 7), Flt3-L(Ligand for Flk2), TSLP 
(Thymic Stromal Lymphopoietin). 
*p<0.05, **p<0.01, ***p<0.001. 
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Figure 2.2-4. 
 
 
 156 
Figure 2.2-4. Hematopoietic stem cells are not impaired in KRNxG7 mice. 
 (A) Immunophenotypic analyses of HSC containing populations. BM from 3, 6 
and 7 week old KRN, B6xG7 and KRNxG7 mice were subjected to FACS 
analyses for cKit, Sca1 and lineage or CD150, CD48 and CD41 markers. The 
frequency ± SD of KSL or SLAM is shown on the Y-axis. (n≥4). 
 (B) Cell Cycle analysis of bone marrow sub-populations.  6-8 week old mice 
were injected with a single dose of bromodeoxy-uridine (BrdU) proportionate to 
body mass for 2-3 hours prior to sacrifice. Different bone marrow fractions were 
analyzed for BrdU incorporation by flow cytometry.  Shown is the mean ± SD of 
BrdU positive cells for each population for 2 independent experiments (n=4-5 
total mice).   
(C) Quiescent Fraction Analysis of Bone Marrow KSL cells.  Bone marrow cells 
from KRNxG7 and B6xG7 mice (n=4-5) of different ages were lineage depleted, 
surface stained for c-Kit and Sca-1 and subjected to intracellular staining for Ki67 
and Hoechst (see methods and Supplementary Figure 2.2-5). Quiescent cells do 
not express Ki67 (Ki67neg) and stain low for Hoechst because of their 2N DNA 
content (versus 4N DNA content of S/G2/M phase cells). Ki67negHoechstlow 
(quiescent cell) fraction of the stem cell enriched Lin-cKit+Sca1+ (KSL) 
population and the non-stem cell enriched Lin-cKit+Sca1- population are shown. 
As expected KSL cells are more quiescent than Lin-cKit+Sca1- progenitors.  
However there is no appreciable difference in quiescent fraction in KRNxG7 KSL 
cells compared with B6xG7 KSL cells.  
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(D) B6xG7 (CD45.2xCD45.2) or KRNxG7 (CD45.2xCD45.2) BM was 
transplanted into lethally irradiated B6xG7 (CD45.1xCD45.2) recipients. 
Peripheral blood was analyzed for donor contribution (CD45.2) every 6 weeks 
after BM transplantation for 6 months. The percentage ± SD of CD45.2+ 
chimerism is shown on the Y-axis (n=4/genotype). 
(E) B6xG7 (CD45.2+) or KRNxG7 (CD45.2+) bone marrow cells (2x105) were 
mixed with B6xG7 (CD45.1+; CD45.2+) competitor bone marrow cells (2x105) 
and injected (i.v.) into lethally irradiated (1000 Rads) B6xG7 (CD45.1xCD45.2) 
recipient mice. PB CD45.2+ cells of were analyzed 3 months and 5 months post-
transplantation. Data represent the average percentages peripheral blood 
chimerism ± s.e.m.  
*p<0.05, **p<0.01 
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Figure 2.2-5. 
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Figure 2.2-5. Characterization of HSCs and progenitors in KRNxG7 spleen.   
(A) Spleen from 1, 2 and 6 week old B6xG7, KRN and KRNxG7 mice were 
subjected to FACS analyses for cKit, Sca1 and lineage markers. The frequency ± 
SD of CD45+KSL- is shown on the Y-axis. (n ≥5).  
(B) BM and spleen cells from 6 week old KRN and KRNxG7 mice were subjected 
to hematopoietic replating assay (n = 3). Hematopoietic colonies were counted 7-
10 days after replating.   
(C) Lin- spleen cells from B6xG7 (CD45.2xCD45.2) or KRNxG7 (CD45.2xCD45.2) 
were transplanted into lethally irradiated B6xG7 (CD45.1xCD45.2) mice. Survival 
rate of the recipients is shown on the left. CD45.2+ cells were analyzed 3 months 
after transplantation. One representative FASC data is shown on the right.  
***p<0.001. 
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Supplementary Figures 2.2-1. 
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Supplementary Figures 2.2-1. In vitro osteoblasts differentiation from 
KRNxG7 bone marrow stromal cells is normal.   
(a) AP quantitative assay for high-density BMSC cultures in osteogenic medium.  
Data is presented as mean ± SD, n=5 in each group of mice.  
(b) Detection of bone nodule formation by von Kossa staining.  The BMSC cells 
were incubated for 14 days in mineralization medium.  (arrowhead denotes a 
nodule) 
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Supplementary Figures 2.2-2. 
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Supplementary Figures 2.2-2. Marrow cellularity and KSL frequency are 
independent of harvesting method.  
(a) Number of bone marrow cells generated from flushing method and 
collagenase/dispase enzymatic digestion method of total bone. One femur and 
one tibia from 6 week old B6xG7 and KRNxG7 mice were examined. The values 
indicate cell number ± SD from one femur plus one tibia on the Y-axis. n=4 for 
each group. 
(b) Flushed BM and total BM from 6 week old B6xG7 and KRNxG7 mice were 
subjected to KSL FACS analyses. The values indicate frequency ± SD of KSL on 
the Y-axis. 
(c) Absolute number of KSL cells of one femur and one tibia of B6xG7 and 
KRNxG7. The values indicate cell number ± SD on the Y-axis. n=4 for each 
group, *p<0.05. 
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Supplementary Figures 2.2-3. 
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Supplementary Figures 2.2-3. Depleted lymphoid cells in KRNxG7 bone 
marrow. 
(a) Representative FACS plot depicting depleted lymphoid cells and expanded 
myeloid cells in KRNxG7 bone marrow. Lymphoid cells have low forward scatter 
(FSC)  and side scatter (SSC) as a result of the smaller size and less granularity. 
In bone marrow majority of lymphoid cells are B220+ (~30% of leukocytes). This 
reduced FSCloSSClo frequency in KRNxG7 mice is also reflected in B220+ 
frequency (see Figure 2.2-3A). 
(b) Representative FACS plot depicting depleted CLP in KRNxG7 bone marrow. 
CLPs are Flk2+IL-7Rα+Lin-. Indicated fractions are mean CLP frequency in total 
marrow ± standard deviation. 
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Supplementary Figures 2.2-4. 
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Supplementary Figures 2.2-4. BrdU analysis of progenitor populations. 
(a) Schema for BrdU analysis. Lin+ cells are excluded by magnetic depletion 
using biotin conjugated anti-lineage marker antibodies and also by FACS gating 
by excluding Streptavidin-PerCP-Cy5.5 positive cells. Various gated progenitor 
fractions – Lin-, KSL+, KSL- are subsequently analyzed for BrdU positive cells. 
(b) BrdU analysis of bone marrow progenitor cells at early time point (4wks;) and 
later time point (16wks). N=2-4, *p<0.05. 
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Supplementary Figures 2.2-5. 
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Supplementary Figures 2.2-5. Schema for Ki67/Hoechst analysis. 
(a) Exclusion of Lin+ cells by magnetic depletion and flow cytometric gating (see 
methods & Supplementary Figure 2.2-4a) was performed. Lin- cells were 
subjected to doublet discrimination. 
(b) c-Kit and Sca-1 expression of doublet free and Lin- gated cells to get KLS 
(KLS+) and KLS- populations.  
(c) Ki67 and Hoechst analysis of gated KLS+ and KLS- cells. Quiescent cells are 
Ki67negHoechstlo. The more primitive KLS+ population conspicuously lack Ki67hi 
cells, which are present in KLS- population that are devoid of HSCs. 
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Supplementary Figures 2.2-6. 
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Supplementary Figures 2.2-6. Expression of cell cycle Regulators in BM 
derived KSL cells.   
CD45+KSL cells were FACS sorted from 6 week old KRNxG7 and KRN control 
mice (10-11 mice for each). RNA was extracted and used for quantitative real-
time PCR for various cell cycle regulators: p21 and p27 are cyclin dependent 
kinase (Cdk) inhibitors of the Cip/Kip family; p18 and p19 are Cdk inhibitors of 
the Ink4 family; Rb, p107 and p130 are retinoblastoma (Rb) family genes; Bmi is 
an epigenetic regulator of stem cell self renewal.  Shown is the average of 2-4 
experiments for each gene with error bars representing standard deviation.  Each 
experiment was performed in duplicate. 
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Supplementary Figures 2.2-7. 
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Supplementary Figures 2.2-7. Analyses for donor cell derived 
hematopoietic cell lineages in primary, secondary and tertiary recipients. 
Peripheral blood was analyzed for the donor cell contribution (CD45.2) to 
individual hematopoietic cell lineages. The data shown is the mean percentage 
PB chimerism (CD45.2+) ± SD of CD3+, CD4+, CD8+ (T cells), B220+ (B cells), 
Gr1+ (granulocytes), and Mac-1+ (macrophages) populations. ***p<0.001. 
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Supplementary Figures 2.2-8. 
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Supplementary Figures 2.2-8. HSCs from 4 month old KRNxG7 mice are not 
compromised.   
Lethally irradiated B6xG7 (CD45.1xCD45.2) recipient mice were transplanted 
with 1x106 BM cells from 4 months old B6xG7 (CD45.2xCD45.2) or KRNxG7 
(CD45.2xCD45.2) mice. The figures shown are the mean percentage ± SD of 
donor-derived cells in the peripheral blood (PB) 6 weeks after transplantation. (a) 
The percentage CD45.2+ donor derived cells is shown. (b) Donor derived mature 
hematopoietic cell populations are detected as CD4/CD8, B220, and Mac-1 
positive populations.  n=8, ***p<0.001 
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Supplementary Figures 2.2-9. 
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Supplementary Figures 2.2-9. Splenomegaly in KRNxG7 mice. 
(a) KRNxG7 mice display splenomegaly. KRNxG7 spleen weight was compared 
to that of control mice.  Left panel shows quantified mean spleen weight 
normalized to total body weight using KRN controls ± SD. n=5. Right panel 
shows representative spleens from KRNxG7 and control B6xG7 to illustrate 
splenomegaly. 
(b) The spleen of 6 week old KRN, B6xG7, and KRNxG7 were collected, treated 
with RBS lysis buffer and counted. The values indicate mean cell number ± S.D. 
n≥4. 
(c) Absolute number of KSL cells of spleen cells of B6xG7 and KRNxG7. The 
values indicate cell number ± SD on the Y-axis. n=8 for each group, **p<0.01, 
***p<0.001. 
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Supplementary Table 2.2-1.  Primer sequences used for qRT-PCR.  
 
Gene Forward Primer Reverse Primer Source 
β3 Integrin CCACACGAGGCGTGAACTC CTTCAGGTTACATCGGGGTGA Primerbank 7949057a1 
Bmi-1 ATCCCCACTTAATGTGTGTCCT CTTGCTGGTCTCCAAGTAACG Primerbank 192203a1 
Cathepsin K GAAGAAGACTCACCAGAAGCAG TCCAGGTTATGGGCAGAGATT Primerbank 31982433a1 
Flt3-L AGATGCAAACGCTTCTGGAG AGGTGGGAGATGTTGGTCTG Primer 3 
GAPDH TGGCAAAGTGGAGATTGTTGCC AAGATGGTGATGGGCTTCCCG Ref (Lugus et al., 2007) 
IL-7 TGGAATTCCTCCACTGATCC ACCAGTGTTTGTGTGCCTTG Ref (Ueda et al., 2005) 
OPG GGGCGTTACCTGGAGATCG GAGAAGAACCCATCTGGACATTT Primerbank 31543882a2 
OSCAR CCTAGCCTCATACCCCCAG CAAACCGCCAGGCAGATTG Primerbank 18376821a3 or 28274692a3 
Osteocalcin CTGACCTCACAGATCCCAAGC TGGTCTGATAGCTCGTCACAAG Primerbank 13811695a1 
p107 AGCTTCAGCCACTCAAAGTGTAAG GCTCACTTGGTGCGCTTTTT Ref (Passegue et al., 2005) 
p130 TGATGGCAAAGGTCACAAAAGA GGCCTGTGGCTGAGTCCTGTA Ref (Passegue et al., 2005) 
p18 CGAGCAGCACTCTGGACTAC AGGCTCGGCCATTCTTTAG Primer 3 
p19 CTTCTTCACCGGGAGCTG CAAAGCAACTGCTGGACTTC Primer 3 
p21 GTGGCCTTGTCGCTGTCTT GCGCTTGGAGTGATAGAAATCTG Primerbank 6671726a3 
p27 TCTCTTCGGCCCGGTCAAT GGGGCTTATGATTCTGAAAGTCG Primerbank 31542372a2 
RANKL CAGCATCGCTCTGTTCCTGTA CTGCGTTTTCATGGAGTCTCA Primerbank 8843823a1 
Rb TGACCTGGTAATCTCATTTCAGC GGGTGTTCGAGGTGAACCAT Primerbank 6677679a3 
Runx2 TGTTCTCTGATCGCCTCAGTG CCTGGGATCTGTAATCTGACTCT Primerbank 20806530a2 
TSLP CTCCCCGACAAAACATTTGCC GCCATTTCCTGAGTACCGTCATT Primerbank 10946698a3 
 
? Primerbank: http://pga.mgh.harvard.edu/primerbank/ 
? Primer 3: http://biotools.umassmed.edu/bioapps/primer3_www.cgi 
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Chapter 2.3 
Conclusion and Future Directions 
 
 181 
Summary of Chapter Two 
 During adulthood, hematopoietic stem cells (HSCs) are responsible for the 
generation of all blood cells. Under normal physiological conditions, HSCs reside 
mainly in specific microenvironments within bone marrow (BM) cavities, known as 
BM niches, where they maintain a balance between self-renewal and 
differentiation into more mature cells. Bone homeostasis has been proposed to 
have important effects on HSC maintenance under physiological states, but little 
is known about their relationship in pathological states. In this chapter, the 
relationship between HSCs and bone homeostasis in chronic inflammatory 
conditions is examined using the KRNxG7 transgenic mouse model. Using this 
model, it was found that mice with chronic inflammatory arthritis also develop 
osteoporosis. The overall systemic bone loss phenotype of these mice is not due 
to increased resorption of bone, but rather to decreased bone formation. 
Osteoblasts, bone forming cells, have been proposed to be one of the 
components that comprise the BM niches that maintain HSC homeostasis and 
supports B lymphopoiesis. In our studies, we have found that these arthritic mice 
display defective bone marrow B lymphopoiesis but, intriguingly, HSC frequency, 
cell cycling, and long-term functional repopulating ability were all unchanged, 
compared to normal mice. Our findings indicate that the bone-forming function of 
osteoblasts is disassociated from their ability to maintain HSCs in the bone 
marrow in a chronic inflammatory condition. These observations suggest that 
other cell types, such as endothelial cells in the bone marrow, might serve as 
niche cells to maintain HSC homeostasis under pathological conditions. 
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Hematopoietic Stem Cell Niche in KRNxG7 Mouse 
 We found that KRNxG7 mice, a mouse model to study human RA, exhibit an 
osteoporotic phenotype, due to diminished bone formation. The molecular 
mechanisms that affect the number and function of osteoblasts in the bone 
marrow of KRNxG7 mice remain unclear. Previous in vitro studies demonstrated 
that the pro-inflammatory cytokine, TNFα, inhibits the development and activity of 
osteoblastic cells by down-regulating bone-formation markers including alkaline 
phosphatase, type-I collagen, osteocalcin and Runx2 (Centrella et al., 1988; 
Gilbert et al., 2002; Gilbert et al., 2005; Kuroki et al., 1994; Li and Stashenko, 
1992; Nakase et al., 1997). We have found that KRNxG7 mice display a high level 
of TNF-α mRNA and protein in BM and serum. Thus, it is possible that high level 
of TNFα has an impact on the development and function of osteoblasts in the 
bone marrow. It will be important to assess the effects of TNFα on the 
osteoporotic phenotype in KRNxG7 mice. One experiment would be to use 
antibodies against TNFα to KRNxG7 mice before onset of the arthritic symptoms. 
For example, injection of antibodies to neonatal KRNxG7 mice or to pregnant 
female would determine if they can reduce the osteoblast defects that are seen in 
the tibias and femurs of adult KRNxG7 mice. Furthermore, deletion of TNFα 
signaling in KRNxG7 mice could give a detailed insight on the TNFα-mediated 
osteoporotic phenotype found in these arthritic mice. 
 Previous studies using genetically modified mice have demonstrated that 
osteoblast numbers and activity correlate positively with the number of functional 
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HSCs seen in the bone marrow (Calvi et al., 2003; Visnjic et al., 2004; Zhang et 
al., 2003). However, we revealed that, while the numbers and activity of 
osteoblasts in the bone marrow of KRNxG7 mice were reduced, the maintenance 
of the HSC population was intact. Those data do not, therefore, support the 
previous notion at least in this model of chronic inflammation. I propose two 
possibilities to explain our observations: first, the remaining osteoblasts in arthritic 
mice can sufficiently support the HSC maintenance; second, endothelial cells in 
the bone marrow could compensate the osteoblast defects and sufficiently 
support the HSC maintenance in KRNxG7 mice. 
 When we tracked green fluorescent protein (GFP) expression under the 
control of the osteoblast-specific Col2.3 promoter (Kalajzic et al., 2002), we found 
that some GFP+ cells were still present in KRNxG7 bone marrow (unpublished 
data). These Col2.3 GFP-expressing osteoblasts might be part of the HSC niche 
because conditional ablation of the population leads to a decrease in the total 
number of HSCs found in the bone marrow (Visnjic et al., 2004). Thus, it is 
possible that a limited population of osteoblast cells that remain active in KRNxG7 
mice might still be sufficient to maintain HSC integrity in the bone marrow of 
arthritic mice. Another possibility is that osteoblast-lineage cells are 
multifunctional. It has been proposed in previous studies that a subset of 
osteoblasts, expressing N-cadherin, might serve as HSC niche cells (Arai et al., 
2004; Zhang et al., 2003). Lyperi et al. showed that increasing the activity and 
total number of osteoblasts, without increasing the N-cadherin-expressing 
osteoblast subpopulation, results in excessive bone formation without increasing 
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the number of HSCs (Lymperi et al., 2008). This observation suggests that HSC 
number is correlated, not with the total number of osteoblasts, but with a subset of 
osteoblasts which may not be involved in bone formation. Therefore, it is possible 
that the remaining osteoblasts in KRNxG7 mice, possessing little or no 
bone-forming activity, could be sufficient to maintain HSCs in the bone marrow. 
 To test if the remaining osteoblasts have the ability to maintain HSCs, a 
possible experiment would be to cross KRNxG7 mice with Col2.3?TK transgenic 
mice (Visnjic et al., 2004), which allows conditionally ablation of osteoblasts by 
ganciclovir. This cross could be used to assess whether or not HSC maintenance 
is disturbed by ablation of the remaining osteoblast population seen in KRNxG7 
mice. If the functional HSCs are affected in KRNxG7;Col2.3?TK mice, the result 
would suggest that the remaining osteoblasts are sufficient to serve as HSC niche 
cells. On the other hand, if HSC maintenance is not affected by the ablation, it 
would indicate that other cells play important roles in the HSC maintenance under 
conditions of chronic inflammation. 
 HSCs have been observed to closely attach to the endothelial cells in the BM 
and mobilized spleen, suggesting endothelial cells might serve as important 
components as HSC niche cells (Kiel et al., 2007; Kiel et al., 2005). It is possible 
that inflammatory environment might alter the ability of endothelial cells in the 
bone marrow of arthritic mice, and that the endothelial cells could sufficiently 
support HSC maintenance, compensating for the osteoblast-related defects in the 
KRNxG7 mice. Li et al. showed that endothelial cells, isolated from several adult, 
non-hematopoietic organs and co-cultured with various cytokines, supported the 
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expansion of hematopoietic progenitors, some of which maintained the 
repopulating capacity of HSCs (Li et al., 2004). Cell adhesion molecules (CAMs), 
such as E-selectin and vascular cell adhesion molecule-1 (VCAM-1), are involved 
in hematopoietic progenitor cells homing in to and repopulating the new bone 
marrow after bone marrow transplantation (Frenette et al., 1998; 
Papayannopoulou et al., 1995). These CAMs are constitutively expressed on the 
surfaces of endothelial cells in hematopoietically active tissues, such as adult 
bone marrow and fetal liver (Schweitzer et al., 1996), but not detectable on the 
endothelial cells of non-hematopoietic tissues under normal conditions. 
Interestingly, these molecules can be upregulated in conditions of inflammation or 
by various inflammatory cytokines (Haraldsen et al., 1996; Iademarco et al., 1995; 
Schweitzer et al., 1996; Strickland et al., 1997). We have found that KRNxG7 
mice have enlarged spleens with accumulations of HSCs and hematopoietic 
progenitors, despite the fact that osteoblasts are not found in the spleen. 
 Therefore, it is critical to examine whether endothelial calls are responsible 
for the HSC maintenance in the bone marrow and for the accumulated HSCs in 
the spleens of arthritic mice. A possible approach to this question is to examine 
histological sections of spleen and tibia/femur from KRNxG7 and control mice (i.e. 
G7 or KRN mice), double-staining with HSC markers, such as CD150+CD41- 
CD48- (Kiel et al., 2005), and with endothelial cell makers, such as MECA-32 or 
VE-cadherin, to determine if HSCs reside in proximity to endothelial cells in these 
tissues. If HSCs reside more closely to the endothelial cells comparing to other 
cell types in KRNxG7 mice versus control mice, it would provide an insight that 
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the endothelial cells might play significant roles for the HSC maintenance in 
chronic inflammation conditions. Furthermore, determining the expression levels 
of CAMs such as E-selectin and VCAM-1 on the endothelial cells of the spleen 
and tibia/femur of KRNxG7 versus control mice would be warranted. Next, to 
disturb the assembly of BM endothelial cells in KRNxG7 and control mice by using 
VE-cadherin-specific antibody (Avecilla et al., 2004) followed by HSC analyses 
would further elucidate the roles of endothelial cells in HSC maintenance under 
normal vs. pathologic conditions. Future analyses comparing gene expressions of 
isolated endothelial cells from spleen and bone marrow between KRNxG7 and 
control mice would provide further understanding of how chronic inflammation 
might affect bone marrow and splenic endothelial cells to support HSC 
maintenance molecularly. 
 Moreover, the bone marrow microenvironment contains diverse populations 
of non-hematopoietic cells such as mesenchymal progenitors, osteoblasts, 
osteoclasts, fibroblasts, reticular cells, adipocytes, and endothelial cells. Future 
studies will require further determining the involvements of these cells or even 
unidentified cell types in supporting HSC maintenance in the bone marrow of 
KRNxG7 mice. 
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